Anti-CD73 antibodies and their applications
By designing specific anti-CD73 antibodies, using their high affinity binding to CD73 and enzymatic activity blockade, the problem of insufficient utilization of CD73 targets in existing anti-tumor treatments has been solved, and the therapeutic effect on a variety of cancers has been significantly improved.
Patent Information
- Application Number
- CN202310968592.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-08-03
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-08-03
AI Technical Summary
The existing anti-tumor treatment methods have not yet effectively utilized CD73 as a target, resulting in insufficient efficacy in tumor treatment.
An anti-CD73 antibody was developed that can efficiently and specifically bind CD73 through specific sequence designs of its heavy and light chain variable regions, thereby inhibiting its biological activity, and is used to prevent and treat multiple types of cancer.
This antibody significantly inhibits the enzyme activity of CD73, promotes its endocytosis, demonstrates a powerful anti-tumor effect, can combine with CD73 with high affinity, significantly improves the efficacy of treating a variety of cancers.
Smart Images

Figure BDA0004374366670000101 
Figure BDA0004374366670000102 
Figure BDA0004374366670000111
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and specifically to an anti-CD73 antibody and applications thereof. Background Art
[0002] CD73, also known as ecto-5'-nucleotidase (ecto-5'NT, EC 3.1.3.5), has a protein molecular weight of approximately 70 kDa and is an enzyme anchored on the cell surface by glucosylphosphatidylinositol (GPI). CD73 is present in most tissues, especially in endothelial cells and hematopoietic cell subsets (Resta et al., Immunol Rev 1998; 161: 95-109 and Colgan et al., Prinergic Signal 2006; 2: 351-60). CD39 upstream of CD73 can catalyze ATP to produce adenosine monophosphate (AMP), and the produced AMP is catalyzed and hydrolyzed into adenosine by CD73. Adenosine is a widely studied signal transduction molecule whose biological effects are mediated by several receptors (including A1, A2A, A2B and A3). In the tumor microenvironment, adenosine can not only enhance tumor proliferation, angiogenesis and metastasis (Zhang et al., Cancer Res 2010; 70: 6407-11), but also significantly inhibit anti-tumor immune response (F. Ghiringhelli et al., Biomed. Res, Int. 2012). Therefore, CD73 is regarded as a powerful cancer treatment target.
[0003] CD73 is expressed on many different cancers, including colorectal cancer, lung cancer, pancreatic cancer, ovarian cancer, bladder cancer, leukemia, glioma, glioblastoma, melanoma, thyroid cancer, esophageal cancer, prostate cancer and breast cancer (Jin et al., Cancer Res 2010; 70: 2245-55 and Stagg et al., PNAS 2010; 107: 1547-52). CD73 also affects multiple aspects of tumorigenesis, such as proliferation, differentiation, adhesion / migration, angiogenesis and metastasis. It promotes the proliferation of tumor cells by regulating cell cycle, apoptosis and signaling pathways such as EGFR, β-catenin / cyclin D1, VEGF and AKT / ERK (Zhi X et al., Clin Exp Metastasis 2007, 24(6):439-448; Turcotte M et al., Cancer Res 2015, 75(21):4494-4503; Wu R et al., Oncol Rep 2016, 35(3):1750-1756; Gao ZW et al., BMC cancer 2017, 17(1):135). Moreover, high expression of CD73 as a biomarker is closely related to poor prognosis of many types of tumors, including breast cancer, lung cancer, ovarian cancer, gastric cancer, kidney cancer, head and neck cancer, etc. In addition to cancer cells, a variety of immune cells such as B cells, T cells, Th cells and CD8+T cells also express CD73 molecules (Ghasem G et al., 2019, 23: 2, 127-142). Given the key role of CD73 in tumor growth and metastasis, it has become one of the hot targets in the field of tumor immunotherapy. Several companies are already in phase 2 or phase 1 clinical trials, but no drugs targeting this target have been approved for marketing. Summary of the invention
[0004] The present invention provides anti-CD73 antibodies and their use in disease treatment. The provided antibodies can specifically bind to CD73 and show anti-tumor effects.
[0005] The first aspect of the present invention provides an anti-CD73 antibody or antigen-binding fragment, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region: comprises a HCDR sequence as shown in SEQ ID NOs: 1, 2 and 3, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 1, 2 and 3; or comprises a HCDR sequence as shown in SEQ ID NOs: 4, 5 and 6, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 4, 5 and 6; or comprises a HCDR sequence as shown in SEQ ID NOs: 7, 8 and 9, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 7, 8 and 9; or comprises a HCDR sequence as shown in SEQ ID NOs: 10, 11 and 12, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 10, 11 and 12; or comprises a HCDR sequence as shown in SEQ ID NOs: 13, 14 and 15, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: NO: 13, 14 and 15 HCDR sequence with one, two or three conservative amino acid mutations; or comprising SEQ ID NO: 16, 17 and 18 HCDR sequence, or a sequence with one, two or three conservative amino acid mutations with the HCDR sequence of SEQ ID NO: 16, 17 and 18; or comprising SEQ ID NO: 19, 20 and 21 HCDR sequence, or a sequence with one, two or three conservative amino acid mutations with the HCDR sequence of SEQ ID NO: 19, 20 and 21; the light chain variable region: comprising SEQ ID NO: 22, 23 and 24 LCDR sequence, or a sequence with one, two or three conservative amino acid mutations with the LCDR sequence of SEQ ID NO: 22, 23 and 24; or comprising SEQ ID NO: 22, 23 and 25 LCDR sequence, or a sequence with one, two or three conservative amino acid mutations with the LCDR sequence of SEQ ID NO: 22, 23 and 25; or comprising SEQ ID NO: The LCDR sequence shown in SEQ ID NOs: 26, 27 and 28, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NOs: 26, 27 and 28; or a sequence comprising the LCDR sequence shown in SEQ ID NOs: 29, 30 and 31, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NOs: 29, 30 and 31;Or comprising the LCDR sequence shown in SEQ ID NO: 22, 23 and 32, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NO: 22, 23 and 32; or comprising the LCDR sequence shown in SEQ ID NO: 33, 34 and 35, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NO: 33, 34 and 35; or comprising the LCDR sequence shown in SEQ ID NO: 36, 37 and 38, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NO: 36, 37 and 38. ;
[0006] A second aspect of the present invention provides an anti-CD73 antibody or antigen-binding fragment, comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising complementarity determining regions HCDR1, HCDR2 and HCDR3, the light chain variable region comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein HCDR1 is selected from the sequence shown in SEQ ID NO: 1 or 4 or 7 or 10 or 13 or 16 or 19, HCDR2 is selected from the sequence shown in SEQ ID NO: 2 or 5 or 8 or 11 or 14 or 17 or 20, HCDR3 is selected from the sequence shown in SEQ ID NO: 3 or 6 or 9 or 12 or 15 or 18 or 21, LCDR1 is selected from the sequence shown in SEQ ID NO: 22 or 26 or 29 or 33 or 36, LCDR2 is selected from the sequence shown in SEQ ID NO: 23 or 27 or 30 or 34 or 37, and LCDR3 is selected from the sequence shown in SEQ ID NO: 24 or 25 or 28 or 31 or 32 or 35 or 38.
[0007] The third aspect of the present invention provides an anti-CD73 antibody or antigen-binding fragment, comprising: HCDR1, HCDR2 and HCDR3 sequences of the heavy chain variable region as shown in SEQ ID NO: 39 or 40 or 41 or 42 or 43 or 44 or 45, and LCDR1, LCDR2 and LCDR3 sequences of the light chain variable region as shown in SEQ ID NO: 46 or 47 or 48 or 49 or 50 or 51 or 52.
[0008] The fourth aspect of the present invention provides a bispecific antibody, comprising a first antigen binding portion and a second antigen binding portion; the first antigen binding portion specifically binds to a first epitope, the first antigen binding portion comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising a HCDR sequence as shown in SEQ ID NOs: 1, 2 and 3, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 1, 2 and 3; or comprising a HCDR sequence as shown in SEQ ID NOs: 4, 5 and 6, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 4, 5 and 6; or comprising a HCDR sequence as shown in SEQ ID NOs: 7, 8 and 9, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 7, 8 and 9; or comprising a HCDR sequence as shown in SEQ ID NOs: 10, 11 and 12, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 10, 11 and 12; or comprising a HCDR sequence as shown in SEQ ID NOs: 10, 11 and 12. NO: 13, 14 and 15, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence shown in SEQ ID NO: 13, 14 and 15; or a HCDR sequence shown in SEQ ID NO: 16, 17 and 18, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence shown in SEQ ID NO: 16, 17 and 18; or a HCDR sequence shown in SEQ ID NO: 19, 20 and 21, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence shown in SEQ ID NO: 19, 20 and 21; the light chain variable region comprises a LCDR sequence shown in SEQ ID NO: 22, 23 and 24, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NO: 22, 23 and 24; or a LCDR sequence shown in SEQ ID NO: 22, 23 and 25, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NO: The LCDR sequences shown in SEQ ID NOs: 22, 23 and 25 have one, two or three conservative amino acid mutations; or the LCDR sequences shown in SEQ ID NOs: 26, 27 and 28, or the sequences having one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOs: 26, 27 and 28; or the LCDR sequences shown in SEQ ID NOs: 29, 30 and 31, or the sequences having one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOs: 29, 30 and 31;or comprising a LCDR sequence as shown in SEQ ID NOs: 22, 23 and 32, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence as shown in SEQ ID NOs: 22, 23 and 32; or comprising a LCDR sequence as shown in SEQ ID NOs: 33, 34 and 35, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence as shown in SEQ ID NOs: 33, 34 and 35; or comprising a LCDR sequence as shown in SEQ ID NOs: 36, 37 and 38, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence as shown in SEQ ID NOs: 36, 37 and 38;
[0009] The second antigen binding moiety specifically binds to a second epitope, and the second antigen binding moiety is fused to the first antigen binding moiety.
[0010] A fifth aspect of the present invention provides a bispecific antibody comprising a first antigen binding portion and a second antigen binding portion; the first antigen binding portion specifically binds to a first epitope, the first antigen binding portion comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises complementary determining regions HCDR1, HCDR2 and HCDR3, the light chain variable region comprises complementary determining regions LCDR1, LCDR2 and LCDR3; wherein HCDR1 is selected from the sequence shown in SEQ ID NO: 1 or 4 or 7 or 10 or 13 or 16 or 19, HCDR2 is selected from the sequence shown in SEQ ID NO: 2 or 5 or 8 or 11 or 14 or 17 or 20, HCDR3 is selected from the sequence shown in SEQ ID NO: 3 or 6 or 9 or 12 or 15 or 18 or 21, LCDR1 is selected from the sequence shown in SEQ ID NO: 22 or 26 or 29 or 33 or 36, LCDR2 is selected from the sequence shown in SEQ ID NO: 23 or 27 or 30 or 34 or 37, LCDR3 is selected from the sequence shown in SEQ ID NO: NO: the sequence shown in 24 or 25 or 28 or 31 or 32 or 35 or 38; the second antigen binding portion specifically binds to a second epitope, and the second antigen binding portion is fused to the first antigen binding portion.
[0011] The sixth aspect of the present invention provides a polynucleotide encoding the antibody or antigen-binding fragment described in any one of the first to third aspects, or the bispecific antibody described in any one of the fourth to fifth aspects.
[0012] The seventh aspect of the present invention provides a construct comprising the polynucleotide described in the sixth aspect.
[0013] The eighth aspect of the present invention provides a host cell comprising the polynucleotide described in the sixth aspect or the construct described in the seventh aspect.
[0014] The ninth aspect of the present invention provides a pharmaceutical composition, comprising: the antibody or antigen-binding fragment described in any one of the first to third aspects, or the bispecific antibody described in the fourth to fifth aspects; and a pharmaceutically acceptable carrier.
[0015] The tenth aspect of the present invention provides an antibody conjugate, comprising the antibody or antigen-binding fragment described in any one of the first to third aspects, or the bispecific antibody described in the fourth to fifth aspects; and a functional small molecule connected to the antibody or antigen-binding fragment or the bispecific antibody.
[0016] The eleventh aspect of the present invention provides a kit, which comprises the antibody or antigen-binding fragment described in any one of the first to third aspects, or the bispecific antibody described in any one of the embodiments of the fourth to fifth aspects.
[0017] The twelfth aspect of the present invention provides a method for producing the above-mentioned antibody or antigen-binding fragment or producing the above-mentioned bispecific antibody, comprising: culturing the host cell described in the eighth aspect, and collecting the antibody or antigen-binding fragment or the bispecific antibody from the culture.
[0018] The thirteenth aspect of the present invention provides a method for preventing and / or treating a disease, comprising: administering to a subject in need thereof an effective amount of the antibody or antigen-binding fragment described in any one of the first to third aspects above, or the bispecific antibody described in any one of the fourth to fifth aspects above, or the pharmaceutical composition described in the ninth aspect, or the antibody conjugate described in the tenth aspect.
[0019] The fourteenth aspect of the present invention provides a use of the antibody or antigen-binding fragment described in any one of the first to third aspects, or the bispecific antibody described in any one of the fourth to fifth aspects in the preparation of a drug or a kit or in the preparation of an antibody conjugate. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 Schematic diagram of the structure of a bispecific antibody provided according to an embodiment of the present invention.
[0021] Figure 2 Schematic diagram of the structure of a bispecific antibody provided according to an embodiment of the present invention.
[0022] Figure 3 Schematic diagram of the structure of a bispecific antibody provided according to an embodiment of the present invention.
[0023] Figure 4 Schematic diagram of the structure of a bispecific antibody provided according to an embodiment of the present invention.
[0024] Figure 5 Schematic diagram of the structure of a bispecific antibody provided according to an embodiment of the present invention.
[0025] Figure 6 It is a diagram of the endocytosis results of different anti-CD73 antibodies provided according to the embodiments of the present invention.
[0026] Figure 7 This is a diagram showing the anti-tumor effects of different anti-CD73 antibodies combined with anti-PD-L1 antibodies provided according to an embodiment of the present invention.
[0027] Figure 8 These are the enzyme activity blocking results of different bispecific antibodies provided according to the embodiments of the present invention. DETAILED DESCRIPTION
[0028] The technical solution of the present invention is described in detail below with reference to specific examples. At the same time, in order to facilitate the understanding of those skilled in the art, some terms of the present invention are explained and described. It should be noted that these explanations and descriptions are only used to facilitate the understanding of those skilled in the art and should not be regarded as limiting the scope of protection of the present invention.
[0029] As used in this specification and the claims, "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0030] As used herein, the term "antibody" is used in the broadest sense to refer to a protein or polypeptide comprising an antigen binding site or antigen binding fragment or antigen binding portion, covering natural antibodies and artificial antibodies of various structures, including but not limited to complete antibody forms or antigen binding fragments of antibodies. According to a specific embodiment, the antibody referred to is a monoclonal antibody.
[0031] Herein, the term "bispecific antibody" includes antigen binding moieties that specifically bind to different epitopes of at least two different biomolecules, and also includes antigen binding moieties that specifically bind to at least two epitopes of the same biomolecule. In order to distinguish, the parts of the bispecific antibody that bind to different epitopes of the same antigen or different antigens are described as "first antigen binding moiety" and "second antigen binding moiety", etc. The first antigen binding moiety and the second antigen binding moiety do not indicate the importance, nor the order of binding to the antigen, but are only used to distinguish different epitopes of the antigen or to distinguish binding to different antigens. The "first antigen binding moiety" and "second antigen binding moiety" will also be explained and described below. Unless otherwise stated, the order of binding to the antigen in the listed bispecific antibodies is arbitrary. Of course, when the bispecific antibody specifically binds to different biomolecules, it is possible to bind to more than one antigen epitope of the specific biomolecule. According to a preferred embodiment of the present invention, the bispecific antibody comprises antigen binding moieties that specifically bind to different epitopes of two different target antigens.
[0032] Herein, "complete antibody" or "complete antibody" etc. are used to express the same meaning, indicating a protein comprising at least two heavy chains (H) and two light chains (L) interconnected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated as VH) and a heavy chain constant region (abbreviated as CH). The heavy chain constant region includes a heavy chain constant domain CH1, a heavy chain constant domain CH2, and a heavy chain constant domain CH3. Each light chain consists of a light chain variable region (abbreviated as VL) and a light chain constant domain CL. The VH and VL regions can be further divided into complementary determining regions (also called hypervariable regions or hypervariable regions, abbreviated as CDRs), which are separated by conserved framework regions (FRs). Each VH and VL contains three CDRs and four FRs, arranged in the following sequence from the amino terminus (N-terminus) to the carboxyl terminus (C-terminus): FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The CDRs of the heavy chain variable region are respectively referred to as HCDR1, HCDR2 and HCDR3 starting from the amino terminus, and the CDRs of the light chain variable region are respectively referred to as LCDR1, LCDR2 and LCDR3 starting from the amino terminus.
[0033] "Antigen binding fragment", or "antigen binding portion" (such as the first antigen binding portion, the second antigen binding portion) or "antigen binding site" refers to a portion of a full-length antibody that exhibits the property or function of binding to an antigen. The term "variable region" or "variable domain" refers to the domain involved in the binding of an antigen to an antibody heavy chain or light chain. As mentioned above, the hypervariable or hypervariable regions of the heavy and light chains of a complete antibody exhibit specific binding to an antigen. Examples of antigen binding fragments or antigen binding portions include, but are not limited to, Fab, Fab', F(ab')2, bispecific Fab' and Fv fragments (variable regions), linear antibodies, single-chain antibodies, single-domain antibodies, and the like. Papain digestion of a complete antibody produces two identical antigen binding fragments, called Fab fragments, each of which contains a heavy chain and light chain variable region and a light chain constant domain and a heavy chain constant domain CH1. The Fab' fragment differs from the Fab fragment by having a few additional residues at the carboxyl terminus of the heavy chain constant domain CH1, including one or more cysteines from the hinge region of the antibody. Pepsin digestion of a complete antibody yields a F(ab')2 fragment. The F(ab')2 fragment has two antigen-binding F(ab) parts linked together by a disulfide bond, and the F(ab')2 fragment is a bivalent antibody. A single-chain antibody is a fusion protein formed by connecting the variable region of the heavy chain and the variable region of the light chain of an antibody through a flexible short peptide consisting of about 10-25 amino acids. A single-domain antibody is an antibody fragment consisting of the variable region of a single monomer. Since single-domain antibodies are usually derived from the variable region of the heavy chain of camelid antibodies or shark antibodies, they are often called nanobodies. Nanobodies contain only the heavy chain CDR region and are the smallest antigen-binding fragment with complete functions. Nanobodies include three CDR regions (CDR1-CDR3) and four framework regions FR (FR1-FR4). Framework regions FR1, FR2, FR3 and FR4 are separated by complementary determining regions CDR1, CDR2 and CDR3, respectively. Antigen-binding fragments can be obtained by recombinant means. For example, a nucleic acid encoding the target antigen-binding fragment can be constructed, introduced into an expression vector, and expressed in a suitable host to produce the antigen-binding fragment.
[0034] When the term "and / or" is used to connect two or more optional items, it should be understood to mean any one of the optional items or any two or more of the optional items.
[0035] The term "comprising" or "including" means including the mentioned elements or steps, but not excluding other elements or steps. Of course, unless otherwise stated, comprising or including also covers the situation consisting of the mentioned elements or steps. For example, when referring to an antibody variable region comprising a specific sequence, it is also intended to cover the antibody variable region consisting of the specific sequence.
[0036] The "affinity" or "binding affinity" mentioned herein is understood according to the common meaning in the art, and is used to reflect the strength and / or stability of the binding sites between an antigen and an antibody or an antigen-binding fragment.
[0037] "Specific binding" or "specifically binds to", "binds to", "specifically targets" a specific antigen or epitope, or "has specificity" or "can bind to" a specific antigen or epitope means to distinguish it from non-specific interactions, and this specific binding can be measured by some methods commonly used in the art. The ability of an antibody to bind to an antigen can be measured by enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art. For example, cells carrying antigens can be detected by flow cytometry, and the competitive binding between the antibody to be tested and the labeled antibody can be detected by measuring the positive rate index of the cells. Since the spatial structure of the antigen on the cell surface is closer to the form existing in the body, this method can better reflect the real situation. In combination with the specific embodiments of the present invention, the anti-CD73 antibodies provided have EC50 values of ≤10nM, ≤5nM, ≤1nM, ≤0.5nM, ≤0.1nM, ≤0.09nM, ≤0.08nM, ≤0.07nM, ≤0.06nM, ≤0.05nM, ≤0.04nM, ≤0.03nM, ≤0.02nM, and ≤0.01nM. In combination with the specific embodiments of the present invention, the provided bispecific antibodies have EC50 values of ≤10nM, ≤5nM, ≤1nM, ≤0.5nM, ≤0.1nM, ≤0.09nM, ≤0.08nM, ≤0.07nM, ≤0.06nM, ≤0.05nM, ≤0.04nM, ≤0.03nM, ≤0.02nM, ≤0.01nM with the CD73 antigen and EC50 values of ≤10nM, ≤5nM, ≤1nM, ≤0.5nM, ≤0.1nM, ≤0.09nM, ≤0.08nM, ≤0.07nM, ≤0.06nM, ≤0.05nM, ≤0.04nM, ≤0.03nM, ≤0.02nM, ≤0.01nM with the PD-L1 antigen. In addition, the binding activity of antibodies and antigens can also be measured by surface plasmon resonance (SPR) or bio-film interferometry (BLI).
[0038] Whether provided herein is an antibody or antigen binding fragment, or a bispecific antibody, or a polynucleotide, it is generally separable or recombinant. "Separable" refers to being able to identify and separate and / or recover from a cell or cell culture expressing a polypeptide or protein. Typically, the isolated polypeptide will be prepared by at least one purification step. "Isolated antibody" refers to being substantially free of other antibodies or their antigen binding fragments having different antigen specificities. "Recombinant" means that antibodies can be produced in exogenous host cells using genetic recombination techniques.
[0039] "Humanized" antibodies generally refer to antibodies based on antigen-binding portions derived from non-human species and based on partial structures and sequences of human immunoglobulin molecules. For example, in humanized antibodies, the entire antibody except for CDR is encoded by a polynucleotide of human origin, which retains the antigen-binding activity while reducing immunogenicity.
[0040] The CDR sequences of the antibodies or bispecific antibodies shown herein can be obtained by combining existing database analysis. The CDR sequences of the first antigen-binding portion of the anti-CD73 antibody or bispecific antibody provided, and the CDR sequences of the second antigen-binding portion are obtained in combination with the IMGT definition scheme (Ehrenmann F., Kaas Q. and Lefranc M.-P. Nucleic Acids Res., 38: D301-D307 (2010); Ehrenmann, F., Lefranc, M.-P. Cold Spring Harbor Protoc., 6: 737-749 (2011)). It can also be obtained by definition schemes such as Kabat (for example, see USDept. of Health and Human Servies, "Sequences of Proteins of Immunological Interest" (1983)), Chothia (for example, see J. Mol. Biol. 196: 901-917 (1987)). It is known to those skilled in the art that the differences in CDRs caused by differences in definition methods are also included in the protection scope of the present invention.
[0041] Antibodies or antigen-binding fragments
[0042] The present invention provides an anti-CD73 antibody or antigen-binding fragment, comprising HCDR1, HCDR2 and HCDR3 sequences of the heavy chain variable region as shown in SEQ ID NO: 39 or 40 or 41 or 42 or 43 or 44 or 45, and LCDR1, LCDR2 and LCDR3 sequences of the light chain variable region as shown in SEQ ID NO: 46 or 47 or 48 or 49 or 50 or 51 or 52. The provided antibody or antigen-binding fragment contains HCDR1, HCDR2 and HCDR3 sequences, and LCDR1, LCDR2 and LCDR3 sequences, which can be obtained by combining different definition schemes of the heavy chain variable region shown in SEQ ID NO: 39 or 40 or 41 or 42 or 43 or 44 or 45, and by combining different definition schemes of the light chain variable region shown in SEQ ID NO: 46 or 47 or 48 or 49 or 50 or 51 or 52. It should be noted that the CDR sequences obtained through these heavy chain variable regions and light chain variable regions, as part of the anti-CD73 antibody, can also form different heavy chain variable region or light chain variable region sequences with framework region sequences from different sources when forming heavy chain variable region or light chain variable region sequences. These changes are all included in the scope of protection of the present invention.
[0043] According to an embodiment of the present invention, the present invention provides an anti-CD73 antibody or antigen-binding fragment, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR sequence as shown in SEQ ID NOs: 1, 2 and 3, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 1, 2 and 3; or comprises a HCDR sequence as shown in SEQ ID NOs: 4, 5 and 6, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 4, 5 and 6; or comprises a HCDR sequence as shown in SEQ ID NOs: 7, 8 and 9, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 7, 8 and 9; or comprises a HCDR sequence as shown in SEQ ID NOs: 10, 11 and 12, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 10, 11 and 12; or comprises a HCDR sequence as shown in SEQ ID NOs: 13, 14 and 15, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: NO: 13, 14 and 15 HCDR sequence with one, two or three conservative amino acid mutations; or comprising SEQ ID NO: 16, 17 and 18 HCDR sequence, or a sequence with one, two or three conservative amino acid mutations with the HCDR sequence of SEQ ID NO: 16, 17 and 18; or comprising SEQ ID NO: 19, 20 and 21 HCDR sequence, or a sequence with one, two or three conservative amino acid mutations with the HCDR sequence of SEQ ID NO: 19, 20 and 21; the light chain variable region comprises SEQ ID NO: 22, 23 and 24 LCDR sequence, or a sequence with one, two or three conservative amino acid mutations with the LCDR sequence of SEQ ID NO: 22, 23 and 24; or comprising SEQ ID NO: 22, 23 and 25 LCDR sequence, or a sequence with one, two or three conservative amino acid mutations with the LCDR sequence of SEQ ID NO: 22, 23 and 25; or comprising SEQ ID NO: The LCDR sequences shown in SEQ ID NOs: 26, 27 and 28, or sequences having one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOs: 26, 27 and 28; or sequences comprising the LCDR sequences shown in SEQ ID NOs: 29, 30 and 31, or sequences having one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOs: 29, 30 and 31;Or comprising the LCDR sequence shown in SEQ ID NO: 22, 23 and 32, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NO: 22, 23 and 32; or comprising the LCDR sequence shown in SEQ ID NO: 33, 34 and 35, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NO: 33, 34 and 35; or comprising the LCDR sequence shown in SEQ ID NO: 36, 37 and 38, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NO: 36, 37 and 38. ;
[0044] Herein, "conservative amino acid mutation" means that the amino acid mutation does not cause a significant change in the conformational structure of the protein or polypeptide, and retains its biological activity. The conservative amino acid mutation mentioned may be a mutation between different amino acids with similar physiological and biochemical properties. For example, after conservative amino acid mutation, the provided antibody still retains specific binding activity to CD73. According to an embodiment, the conservative amino acid mutation mentioned may be a substitution, deletion or addition of a conservative amino acid. According to a specific embodiment, the deletion of a conservative amino acid is the deletion of one, two or three amino acids on the basis of the listed CDR sequence. According to a specific embodiment, the increase of a conservative amino acid is the addition of one, two or three amino acids on the basis of the listed CDR sequence. According to a specific embodiment, "conservative amino acid substitution" means replacing another amino acid residue with a different amino acid residue having a side chain with similar physiological and chemical properties. For example, conservative amino acid substitutions may occur between amino acid residues with hydrophobic side chains (e.g., Met, Ala, Val, Leu, and Ile), between residues with neutral hydrophilic side chains (e.g., Cys, Ser, Thr, Asn, and Gln), between residues with acidic side chains (e.g., Asp, Glu), between amino acids with basic side chains (e.g., His, Lys, and Arg), or between residues with aromatic side chains (e.g., Trp, Tyr, and Phe). As is known in the art, conservative amino acid substitutions generally do not cause significant changes in the conformational structure of the protein, and thus the biological activity of the protein can be retained. The conservative amino acid substitutions mentioned may be 1 conservative amino acid substitution, 2 conservative amino acid substitutions, 3 conservative amino acid substitutions, and the like. The names of the amino acids used herein are represented by standard single-letter or three-letter codes commonly used in the art. In some embodiments, the HCDR sequence provided has a conservative amino acid substitution with the HCDR sequence shown. In some embodiments, the HCDR sequences provided have a conservative amino acid deletion from the HCDR sequences shown. In some embodiments, the HCDR sequences provided have a conservative amino acid addition from the HCDR sequences shown. In some embodiments, the LCDR sequences provided have a conservative amino acid substitution from the LCDR sequences shown. In some embodiments, the LCDR sequences provided have a conservative amino acid deletion from the LCDR sequences shown. In some embodiments, the LCDR sequences provided have a conservative amino acid addition from the LCDR sequences shown.
[0045]
[0046]
[0047] The present invention also provides an anti-CD73 antibody or antigen-binding fragment, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein HCDR1 is selected from the sequence shown in SEQ ID NO: 1 or 4 or 7 or 10 or 13 or 16 or 19, HCDR2 is selected from the sequence shown in SEQ ID NO: 2 or 5 or 8 or 11 or 14 or 17 or 20, HCDR3 is selected from the sequence shown in SEQ ID NO: 3 or 6 or 9 or 12 or 15 or 18 or 21, LCDR1 is selected from the sequence shown in SEQ ID NO: 22 or 26 or 29 or 33 or 36, LCDR2 is selected from the sequence shown in SEQ ID NO: 23 or 27 or 30 or 34 or 37, and LCDR3 is selected from the sequence shown in SEQ ID NO: 24 or 25 or 28 or 31 or 32 or 35 or 38.
[0048] According to a specific embodiment, the provided antibody or antigen-binding fragment thereof comprises the HCDR sequence shown in SEQ ID NO: 1, 2 and 3, and the LCDR sequence shown in SEQ ID NO: 22, 23 and 24. According to a specific embodiment, the provided antibody or antigen-binding fragment thereof comprises the HCDR sequence shown in SEQ ID NO: 4, 5 and 6, and the LCDR sequence shown in SEQ ID NO: 22, 23 and 25. According to a specific embodiment, the provided antibody or antigen-binding fragment thereof comprises the HCDR sequence shown in SEQ ID NO: 7, 8 and 9, and the LCDR sequence shown in SEQ ID NO: 26, 27 and 28. According to a specific embodiment, the provided antibody or antigen-binding fragment thereof comprises the HCDR sequence shown in SEQ ID NO: 10, 11 and 12, and the LCDR sequence shown in SEQ ID NO: 29, 30 and 31. According to a specific embodiment, the provided antibody or antigen-binding fragment thereof comprises the HCDR sequence shown in SEQ ID NO: 13, 14 and 15, and the LCDR sequence shown in SEQ ID NO: 22, 23 and 32. According to a specific embodiment, the provided antibody or antigen-binding fragment thereof comprises the HCDR sequences shown in SEQ ID NOs: 16, 17 and 18, and the LCDR sequences shown in SEQ ID NOs: 33, 34 and 35. According to a specific embodiment, the provided antibody or antigen-binding fragment thereof comprises the HCDR sequences shown in SEQ ID NOs: 19, 20 and 21, and the LCDR sequences shown in SEQ ID NOs: 36, 37 and 38.
[0049] In some embodiments, the antibodies or antigen-binding fragments provided include a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region is a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence shown in SEQ ID NO: 39 or 40 or 41 or 42 or 43 or 44 or 45, and the light chain variable region is a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence shown in SEQ ID NO: The sequences shown in NO:46 or 47 or 48 or 49 or 50 or 51 or 52 have a sequence with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity.
[0050]
[0051]
[0052] The "sequence identity", "sequence homology" and "sequence similarity" mentioned herein refer to the degree of sequence identity when two polypeptides, proteins or nucleotide sequences are compared. In order to determine the ratio of sequence identity, it can be achieved in a variety of ways known in the art. For example, it can be obtained using public software such as BLAST, ALIGN, BLAST-2 and other software. In some specific embodiments, the sequence identity is due to conservative amino acid mutations. According to a specific embodiment, the sequence having sequence identity with the above-mentioned heavy chain variable region or light chain variable region may be due to 1 conservative amino acid mutation, 2 conservative amino acid mutations, 3 conservative amino acid mutations, 4 conservative amino acid mutations, 5 conservative amino acid mutations, 6 conservative amino acid mutations, 7 conservative amino acid mutations, 8 conservative amino acid mutations, 9 conservative amino acid mutations or 10 conservative amino acid mutations. According to a specific embodiment, the sequence having sequence identity with the above-mentioned heavy chain variable region or light chain variable region differs in the framework region.
[0053] According to a specific embodiment, the antibody provided is mab309, which comprises a heavy chain variable region as shown in SEQ ID NO:39 and a light chain variable region as shown in SEQ ID NO:46. According to a specific embodiment, the antibody provided is mab307, which comprises a heavy chain variable region as shown in SEQ ID NO:40 and a light chain variable region as shown in SEQ ID NO:47. According to a specific embodiment, the antibody provided is mab144, which comprises a heavy chain variable region as shown in SEQ ID NO:41 and a light chain variable region as shown in SEQ ID NO:48. According to a specific embodiment, the antibody provided is mab235, which comprises a heavy chain variable region as shown in SEQ ID NO:42 and a light chain variable region as shown in SEQ ID NO:49. According to a specific embodiment, the antibody provided is mab451, which comprises a heavy chain variable region as shown in SEQ ID NO:43 and a light chain variable region as shown in SEQ ID NO:50. According to a specific embodiment, the antibody provided is mab540, which comprises a heavy chain variable region as shown in SEQ ID NO:44 and a light chain variable region as shown in SEQ ID NO:51. According to a specific embodiment, the antibody provided is mab449, which comprises a heavy chain variable region as shown in SEQ ID NO: 45 and a light chain variable region as shown in SEQ ID NO: 52. The antibody shown exhibits specific binding to CD73, for example, exhibits strong specific binding activity to mammalian CD73. The heavy chain constant domain of these antibodies mentioned is shown in SEQ ID NO: 100, and the light chain constant domain sequence is shown in SEQ ID NO: 101.
[0054] The provided antibodies or antigen-binding fragments may also be humanized. By humanization, the immunogenicity of the antibodies or antigen-binding fragments may be reduced while maintaining binding activity with the target antigen. In some embodiments, the provided antibodies or antigen-binding fragments include a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence shown in SEQ ID NO: 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65, and a light chain variable region having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence shown in SEQ ID NO: NO:66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity of the light chain variable region. According to a specific embodiment, the antibody provided is mab309hu1, which comprises the heavy chain variable region of SEQ ID NO:53 and the light chain variable region of SEQ ID NO:66. According to a specific embodiment, the antibody provided is mab309hu3, which comprises the heavy chain variable region of SEQ ID NO:54 and the light chain variable region of SEQ ID NO:67. According to a specific embodiment, the antibody provided is mab144hu1, which comprises a heavy chain variable region as shown in SEQ ID NO:55 and a light chain variable region as shown in SEQ ID NO:68. According to a specific embodiment, the antibody provided is mab144hu2, which comprises a heavy chain variable region as shown in SEQ ID NO:56 and a light chain variable region as shown in SEQ ID NO:69. According to a specific embodiment, the antibody provided is mab451hu1, which comprises a heavy chain variable region as shown in SEQ ID NO:57 and a light chain variable region as shown in SEQ ID NO:70. According to a specific embodiment, the antibody provided is mab451hu3, which comprises a heavy chain variable region as shown in SEQ ID NO:58 and a light chain variable region as shown in SEQ ID NO:71. According to a specific embodiment, the antibody provided is mab451hu4, which comprises a heavy chain variable region as shown in SEQ ID NO:59 and a light chain variable region as shown in SEQ ID NO:72. According to a specific embodiment, the antibody provided is mab451hu5, which comprises a heavy chain variable region shown in SEQ ID NO:60 and a light chain variable region shown in SEQ ID NO:73.According to a specific embodiment, the antibody provided is mab451hu6, which comprises a heavy chain variable region as shown in SEQ ID NO:60 and a light chain variable region as shown in SEQ ID NO:74. According to a specific embodiment, the antibody provided is mab540hu1, which comprises a heavy chain variable region as shown in SEQ ID NO:61 and a light chain variable region as shown in SEQ ID NO:75. According to a specific embodiment, the antibody provided is mab540hu3, which comprises a heavy chain variable region as shown in SEQ ID NO:62 and a light chain variable region as shown in SEQ ID NO:76. According to a specific embodiment, the antibody provided is mab449hu1, which comprises a heavy chain variable region as shown in SEQ ID NO:63 and a light chain variable region as shown in SEQ ID NO:77. According to a specific embodiment, the antibody provided is mab449hu3, which comprises a heavy chain variable region as shown in SEQ ID NO:64 and a light chain variable region as shown in SEQ ID NO:78. According to a specific embodiment, the antibody provided is mab449hu4, which comprises a heavy chain variable region as shown in SEQ ID NO:65 and a light chain variable region as shown in SEQ ID NO:79. The heavy chain constant domain of these antibodies is shown in SEQ ID NO:100, and the light chain constant domain sequence is shown in SEQ ID NO:101.
[0055]
[0056]
[0057]
[0058] According to a specific embodiment, the provided antibodies bind to human CD73 or monkey (e.g., cynomolgus) CD73 with an EC50 of 10 nM or less, for example, the affinity EC50 value for CD73 is less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.8 nM, less than 0.5 nM, less than 0.3 nM, or less than 0.1 nM, less than 0.05 nM. The provided antibodies can also promote CD73 endocytosis and exhibit anti-tumor activity.
[0059] The anti-CD73 antibodies provided may be from any of the commonly known isotypes, including but not limited to IgA, IgG, IgM and secretory IgA. IgG isotypes can be divided into different subclasses in different species, for example, IgG1, IgG2, IgG3 and IgG4 in humans, and IgG1, IgG2a, IgG2b and IgG3 in mice. According to an embodiment, the provided antibody further includes an Fc region, and the Fc region mentioned may be derived from a natural Fc region or a modified Fc region. The natural Fc region may be of any origin, including but not limited to mouse, primate, human, preferably human Fc region. The human Fc region mentioned can be obtained in a public database.
[0060] Bispecific Antibodies
[0061] Bispecific antibodies (BsAb) are antibodies that can specifically bind to two antigens or antigenic epitopes at the same time. Since Nisonoff and his collaborators first proposed the concept of BsAb in 1960, bispecific antibodies have developed rapidly with the gradual maturity of genetic engineering antibody technology. Because BsAb can target multiple antigens or antigenic epitopes, it has more advantages than monoclonal antibodies, and has gradually shown higher efficacy than monoclonal antibody combination therapy. For example, specific immune effector cells can be redirected to adjacent tumor cells to enhance tumor killing; and the specificity of binding can be increased through the interaction of two different cell surface antigens; at the same time, compared with the combination of single antibodies, the development cost can be reduced, and there is no need to balance the different half-lives of the two antibodies resulting in different dosing times, and the toxicity is low. The development of bispecific antibodies related to the CD73 target has a wide range of applications in the fields of tumor treatment and autoimmune diseases. Bispecific antibodies are used to treat diseases and show excellent disease treatment effects.
[0062] The present invention provides a bispecific antibody, comprising a first antigen binding portion and a second antigen binding portion, wherein the first antigen binding portion and the second antigen binding portion specifically bind to different epitopes, respectively. The different epitopes mentioned may be from different epitopes of the same antigen, or from different epitopes of different antigens. According to a specific embodiment of the present invention, the bispecific antibody provided comprises a first antigen binding portion and a second antigen binding portion, wherein the first antigen binding portion specifically binds to the first epitope, the second antigen binding portion specifically binds to the second epitope, and the first antigen binding portion and the second antigen binding portion are fused. The first epitope and the second epitope may be from the same antigen or from different antigens. According to a preferred embodiment of the present invention, the first antigen binding portion specifically binds to the first epitope, and the second antigen binding portion specifically binds to the second epitope from different antigens. As shown in the text, the terms "first" and "second" are used only for descriptive purposes, and cannot be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated, nor are they used to indicate a sequential order. The terms "first antigen-binding portion" and "second antigen-binding portion" respectively refer to portions that can bind to different antigens or different epitopes of the same antigen, which can be a complete antibody or a portion of a complete antibody, such as a heavy chain variable region, a light chain variable region, Fab, Fab', F(ab')2, a single-chain antibody (ScFv), or a single-domain antibody (sdAb), etc.
[0063] The present invention provides a bispecific antibody, comprising a first antigen binding portion and a second antigen binding portion; the first antigen binding portion specifically binds to a first epitope, and the second antigen binding portion specifically binds to a second epitope; the first antigen binding portion comprises HCDR1, HCDR2 and HCDR3 sequences of the heavy chain variable region as shown in SEQ ID NO: 39 or 40 or 41 or 42 or 43 or 44 or 45, and LCDR1, LCDR2 and LCDR3 sequences of the light chain variable region as shown in SEQ ID NO: 46 or 47 or 48 or 49 or 50 or 51 or 52. It should be noted that the CDR sequences mentioned can be obtained by combining different definition schemes of the heavy chain variable region and light chain variable region sequences shown. Those skilled in the art also need to understand that the CDR sequences of the heavy chain variable region and light chain variable region sequences shown are slightly different due to different definition schemes of antibody sequences, such as the classic Kabat amino acid sequence numbering system, IMGT system, Chothia system, etc. mentioned above. The different CDR sequences analyzed are all included in the protection scope of the present invention. These CDR sequences can form different heavy chain variable region sequences or light chain variable region sequences with framework region sequences from different sources, and these changes and differences are also included in the protection scope of the present invention.
[0064] According to an embodiment of the present invention, the present invention also provides a bispecific antibody, comprising a first antigen binding portion and a second antigen binding portion; the first antigen binding portion specifically binds to a first epitope, the second antigen binding portion specifically binds to a second epitope, and the second antigen binding portion is fused to the first antigen binding portion; the first antigen binding portion comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a HCDR sequence as shown in SEQ ID NOs: 1, 2 and 3, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 1, 2 and 3; or comprises a HCDR sequence as shown in SEQ ID NOs: 4, 5 and 6, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 4, 5 and 6; or comprises a HCDR sequence as shown in SEQ ID NOs: 7, 8 and 9, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: 7, 8 and 9; or comprises a HCDR sequence as shown in SEQ ID NOs: 10, 11 and 12, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequence as shown in SEQ ID NOs: NO: 10, 11 and 12 have one, two or three conservative amino acid mutations in the HCDR sequence; or contain the HCDR sequence shown in SEQ ID NO: 13, 14 and 15, or have one, two or three conservative amino acid mutations with the HCDR sequence shown in SEQ ID NO: 13, 14 and 15; or contain the HCDR sequence shown in SEQ ID NO: 16, 17 and 18, or have one, two or three conservative amino acid mutations with the HCDR sequence shown in SEQ ID NO: 16, 17 and 18; or contain the HCDR sequence shown in SEQ ID NO: 19, 20 and 21, or have one, two or three conservative amino acid mutations with the HCDR sequence shown in SEQ ID NO: 19, 20 and 21; the light chain variable region contains the LCDR sequence shown in SEQ ID NO: 22, 23 and 24, or have one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NO: 22, 23 and 24; or contain SEQ ID The LCDR sequence shown in SEQ ID NOs: 22, 23 and 25, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NOs: 22, 23 and 25; or a sequence comprising the LCDR sequence shown in SEQ ID NOs: 26, 27 and 28, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NOs: 26, 27 and 28;or comprising the LCDR sequence shown in SEQ ID NO:29, 30 and 31, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NO:29, 30 and 31; or comprising the LCDR sequence shown in SEQ ID NO:22, 23 and 32, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NO:22, 23 and 32; or comprising the LCDR sequence shown in SEQ ID NO:33, 34 and 35, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NO:33, 34 and 35; or comprising the LCDR sequence shown in SEQ ID NO:36, 37 and 38, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequence shown in SEQ ID NO:36, 37 and 38.;
[0065] The first antigen-binding portion or the second antigen-binding portion of the bispecific antibody mentioned above can be selected as a complete antibody or only a part of the fragment thereof as needed, as long as it can target different target antigens. The first antigen-binding portion or the second antigen-binding portion can be only a heavy chain variable region, Fab, Fab', F(ab')2, single-chain antibody (ScFv), trap, or single-domain antibody (sdAb), etc.
[0066] According to a specific embodiment, the bispecific antibody provided comprises the HCDR sequences shown in SEQ ID NOs: 1, 2 and 3, and the LCDR sequences shown in SEQ ID NOs: 22, 23 and 24. According to a specific embodiment, the bispecific antibody provided has the HCDR sequences shown in SEQ ID NOs: 4, 5 and 6, and the LCDR sequences shown in SEQ ID NOs: 22, 23 and 25. According to a specific embodiment, the bispecific antibody provided has the HCDR sequences shown in SEQ ID NOs: 7, 8 and 9, and the LCDR sequences shown in SEQ ID NOs: 26, 27 and 28. According to a specific embodiment, the bispecific antibody provided comprises the HCDR sequences shown in SEQ ID NOs: 10, 11 and 12, and the LCDR sequences shown in SEQ ID NOs: 29, 30 and 31. According to a specific embodiment, the bispecific antibody provided comprises the HCDR sequences shown in SEQ ID NOs: 13, 14 and 15, and the LCDR sequences shown in SEQ ID NOs: 22, 23 and 32. According to a specific embodiment, the provided bispecific antibody comprises the HCDR sequence shown in SEQ ID NOs: 16, 17 and 18, and the LCDR sequence shown in SEQ ID NOs: 33, 34 and 35. According to a specific embodiment of the present invention, the provided bispecific antibody comprises the HCDR sequence shown in SEQ ID NOs: 19, 20 and 21, and the LCDR sequence shown in SEQ ID NOs: 36, 37 and 38. The HCDR sequence and LCDR sequence shown serve as the first antigen binding portion of the bispecific antibody and specifically bind to the target antigen.
[0067] In some embodiments, the bispecific antibodies provided include the following heavy chain variable regions and light chain variable regions: a heavy chain variable region having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence shown in SEQ ID NO:39 or 40 or 41 or 42 or 43 or 44 or 45 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65, and a light chain variable region having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence shown in SEQ ID NO: NO:46 or 47 or 48 or 49 or 50 or 51 or 52 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 has a light chain variable region with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity. SEQ ID NO:53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 and 65 are humanized heavy chain variable region sequences, respectively. SEQ ID NO: 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78 and 79 are humanized light chain variable region sequences, respectively. The heavy chain variable region and light chain variable region sequences shown are used as the first antigen binding portion of the bispecific antibody, specifically binding to the target antigen. After humanization, the sequences of the heavy chain variable region and light chain variable region of the first antigen binding portion have lower immunogenicity and retain binding activity to the target antigen (such as CD73). The humanized antibody sequence can be obtained by methods commonly used in the art (such as complementary determining region transplantation). In some embodiments, the humanized antibody sequence provided retains the CDR region sequence and replaces the framework region sequence with a human framework region sequence. The human framework region sequence can be obtained by published human sequences. For example, by database comparison and computer homology modeling, a human FR region template with the greatest homology is found, and a comprehensive consideration is given to determine whether the FR region needs to be reverse mutated and the key residues for restoring the mutation, to obtain a high-affinity humanized antibody. These sequences are usually recorded in commonly used databases, such as the PDB protein structure database, IMGT, Genebank and other databases.
[0068] In some embodiments, the first antigen binding portion comprises a heavy chain variable region as shown in SEQ ID NO:39 and a light chain variable region as shown in SEQ ID NO:46. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as shown in SEQ ID NO:40 and a light chain variable region as shown in SEQ ID NO:47. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as shown in SEQ ID NO:41 and a light chain variable region as shown in SEQ ID NO:48. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as shown in SEQ ID NO:42 and a light chain variable region as shown in SEQ ID NO:49. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as shown in SEQ ID NO:43 and a light chain variable region as shown in SEQ ID NO:50. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as shown in SEQ ID NO:44 and a light chain variable region as shown in SEQ ID NO:51. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as shown in SEQ ID NO:45 and a light chain variable region as shown in SEQ ID NO:52. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO:53 and a light chain variable region as set forth in SEQ ID NO:66. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO:54 and a light chain variable region as set forth in SEQ ID NO:67. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO:55 and a light chain variable region as set forth in SEQ ID NO:68. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO:56 and a light chain variable region as set forth in SEQ ID NO:69. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO:57 and a light chain variable region as set forth in SEQ ID NO:70. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO:58 and a light chain variable region as set forth in SEQ ID NO:71. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO:59 and a light chain variable region as set forth in SEQ ID NO:72. In some embodiments, the first antigen binding portion comprises a heavy chain variable region set forth in SEQ ID NO:60 and a light chain variable region set forth in SEQ ID NO:73.In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO:60 and a light chain variable region as set forth in SEQ ID NO:74. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO:61 and a light chain variable region as set forth in SEQ ID NO:75. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO:62 and a light chain variable region as set forth in SEQ ID NO:76. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO:63 and a light chain variable region as set forth in SEQ ID NO:77. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO:64 and a light chain variable region as set forth in SEQ ID NO:78. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO:65 and a light chain variable region as set forth in SEQ ID NO:79.
[0069] According to an embodiment of the present invention, the heavy chain variable region of the first antigen binding moiety is connected to the heavy chain constant domain, and the light chain variable region of the first antigen binding moiety is connected to the light chain constant domain to form an IgG type structure; the second antigen binding moiety is a single domain antibody. According to a specific embodiment of the present invention, the second antigen binding moiety is directly connected to the carboxyl end (C-terminus) of the Fc region or is connected through a connector. According to a specific embodiment of the present invention, the second antigen binding moiety is directly connected to the amino acid (N-terminus) of the heavy chain variable region or light chain variable region of the first antigen binding moiety or is connected through a connector. According to a specific embodiment of the present invention, the second antigen binding moiety is directly connected to the carboxyl end of the light chain constant domain CL of the first antigen binding moiety or is connected through a connector. Of course, when the second antigen binding moiety and the first antigen binding moiety are fused, they may not be limited to the above-mentioned methods, but may also be combined with these fusion methods, or may be connected in other ways.
[0070] According to a preferred embodiment of the present invention, Figure 1 As shown, the heavy chain variable region and the heavy chain constant domain of the first antigen binding part of the bispecific antibody are connected, and the light chain variable region and the light chain constant domain of the first antigen binding part are connected to form an IgG type structure. The second antigen binding part is a single domain antibody. The second antigen binding part is directly connected to the carboxyl terminus of the Fc region through a linker, and the two single domain antibodies are respectively connected to the two ends of the carboxyl terminus of the Fc region through linkers. The two single domain antibodies contained in the second antigen binding part can be the same or different. Of course, as needed, it is also possible to connect only one single domain antibody or more single domain antibodies to one end of the carboxyl terminus of the Fc region. As shown in FIG. Figure 2As shown, the second antigen-binding portion may also include four single-domain antibodies as needed, and two single-domain antibodies are connected to each other at the two ends of the carboxyl terminus of the Fc region. The connected single-domain antibodies may be the same or different. The single-domain antibodies may be connected by a linker.
[0071] According to a preferred embodiment of the present invention, the heavy chain variable region and the heavy chain constant domain of the first antigen binding portion of the bispecific antibody are connected, and the light chain variable region and the light chain constant domain of the first antigen binding portion are connected to form an IgG type structure, and the second antigen binding portion is a single domain antibody, and the second antigen binding portion is connected to the carboxyl terminus of the light chain constant domain through a linker. In at least some embodiments, the second antigen binding portion includes four single domain antibodies, two of which are connected to the carboxyl terminus of the light chain constant domain through a linker, such as Figure 3 As shown. The four single domain antibodies contained in the second antigen binding portion can be the same or different. The second antigen binding portion can also contain only two single domain antibodies as needed, and each single domain antibody is directly connected to the carboxyl end of the light chain constant domain or connected through a linker, such as Figure 5 As shown. The second antigen binding portion may also include four single domain antibodies as needed, one single domain antibody is connected to both ends of the Fc region carboxyl terminus through a linker, and one single domain antibody is connected to the carboxyl terminus of the light chain constant domain through a linker, such as Figure 4 The connected single domain antibodies can be the same or different. The single domain antibodies can be connected by a linker. Figure 1 to Figure 5 The drawings are merely schematic and, for example, the interchain disulfide bonds between the light and heavy chains are not shown in the drawings.
[0072] According to a preferred embodiment of the present invention, the first antigen binding portion, in addition to the heavy chain variable region and light chain variable region mentioned above, further comprises a heavy chain constant domain CH1 and a light chain constant domain to form a (Fab')2 structure, the bispecific antibody further comprises an Fc region, and the second antigen binding portion comprises a single domain antibody, which is connected to the carboxyl end of the light chain constant domain and / or to the carboxyl end of the Fc region. There is no special requirement for the number of single domain antibodies, and the connected single domain antibodies may be the same or different.
[0073] Herein, "linker" and "linker fragment" have the same meaning. The linker can be some oligopeptides or polypeptides, and can be any amino acid sequence that can provide flexibility. Available linkers are linkers commonly used in the art, including but not limited to the following groups: GS, SG, GGS, GSG, SGG, GGG, GGGS, GGGGGSGS, GGGGSGS, GGGGSGGS, GGGGSGGGGSGGGGS, GGGGSGGGGS, GGGGSGGGGSGGGGS, GGGGSGGGGSGGGGS, GGGGSGGGGSGGGGS, GGGGSGGGGSGGGGS, GGGGSGGGGSGGGGSGGGGS, GGGGSGGGGSGGGGSGGGGS, GGGGSGGGGSGGGGSGGGGS, GGGGSGGGGSGGGGSGGGGS, GGGGSGGGGSGGGGSGGGGS, GGGGSGGGGSGGGGSGGGS and the like.
[0074] The second antigen binding moiety mentioned above specifically binds to an antigen different from the first epitope, including but not limited to: PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, 4-1BB, OX40, OX40L, VEGF, VEGF trap, VEGFR, EGFR, GARP, TGF-β, CD47, c-Met, CD3, CD33, TIGIT, PVRIG, CD69, CD96, LEFA1, CD226, FAP2, GITR, CEACAM-1, CD48, TIM-1, VISTA, CD39, CD70, CD27, CD40, Claudin18.2, ICOS, BLTA, B7-H3, BCMA, MUC1 / 16, etc. For example, a commercially available or under-development antibody molecule sequence can be combined with the first antigen binding moiety mentioned herein to form a bispecific antibody to exert a disease treatment effect. Taking PD-1 antibody as an example, partial or full sequences of antibody molecules such as Nivolumab, toripalimab, camrelizumab, tislelizumab, etc. can be fused with the first antigen binding portion mentioned in this article to form a bispecific antibody to play a role. Taking PD-L1 antibody as an example, partial or full sequences of antibody molecules such as durvalumab, atezolizumab, avelumab, etc. can be fused with the first antigen binding portion mentioned in this article to form a bispecific antibody to play a role. For another example, the second antigen binding portion can be a VEGF trap structure. Aflibercept (VEGF-trap) can specifically target VEGFA, VEGFB and PIGF, which prevents angiogenesis by specifically binding and capturing these proteins. The VEGF-trap molecule can be combined with the first antigen binding portion to form a bispecific antibody to exert a disease treatment effect. Bevacizumab is a recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody that can bind to VEGFA, inhibit its binding to VEGFR2, and then inhibit the biological effects of VEGF. Partial or entire sequences of bevacizumab or its biosimilar antibody molecules can be fused with the first antigen binding portion mentioned in this article to form a bispecific antibody to exert its effect.
[0075] According to a specific embodiment, the present invention provides a bispecific antibody, comprising a first antigen binding portion and a second antigen binding portion, the first antigen binding portion specifically binds to CD73, and the second antigen binding portion specifically binds to PD-L1. As mentioned above, as long as the second antigen binding portion can specifically target PD-L1, its expression form is not limited. For example, it can be a complete antibody or a part of a complete antibody, including but not limited to a heavy chain variable region, Fab, Fab', F(ab')2, a single-chain antibody or a nanobody, etc. The second antigen binding portion can be obtained by antibody library screening as needed, or it can be derived from commercially available or existing (for example, disclosed in the literature or clinically studied) antibody sequences. In some specific embodiments, the second antigen binding portion is a single domain antibody. According to a preferred embodiment of the present invention, the bispecific antibody further includes an Fc region, the Fc region is fused to the first antigen binding portion to form an IgG-type structure, and the second antigen binding portion is directly connected to the carboxyl end (also called the C-terminus) of the Fc region or connected through a linker.
[0076] In some embodiments, the second antigen binding portion provided comprises CDR1, CDR2 and CDR3, wherein CDR1 is selected from the sequence shown in SEQ ID NO: 80, 83 or 86, or a sequence having one or two conservative amino acid mutations compared to SEQ ID NO: 80, 83 and 86; CDR2 is selected from the sequence shown in SEQ ID NO: 81, 84 or 87, or a sequence having one or two conservative amino acid mutations compared to SEQ ID NO: 81, 84 and 87; and CDR3 is selected from the sequence shown in SEQ ID NO: 82, 85, 88 or 89, or a sequence having one, two or three conservative amino acid mutations compared to SEQ ID NO: 82, 85, 88 and 89. As mentioned above, it should be known to those skilled in the art that when CDR regions are characterized using different databases, the characterized CDR region sequences will be different, and these differences should also be included in the scope of protection of the present invention.
[0077] According to a specific embodiment, the second antigen binding portion comprises a CDR1 sequence shown in SEQ ID NO: 80, a CDR2 sequence shown in SEQ ID NO: 81, and a CDR3 sequence shown in SEQ ID NO: 82. According to a specific embodiment, the second antigen binding portion comprises a CDR1 sequence shown in SEQ ID NO: 83, a CDR2 sequence shown in SEQ ID NO: 84, and a CDR3 sequence shown in SEQ ID NO: 85. According to a specific embodiment, the second antigen binding portion comprises a CDR1 sequence shown in SEQ ID NO: 86, a CDR2 sequence shown in SEQ ID NO: 87, and a CDR3 sequence shown in SEQ ID NO: 88. According to a specific embodiment, the second antigen binding portion comprises a CDR1 sequence shown in SEQ ID NO: 80, a CDR2 sequence shown in SEQ ID NO: 81, and a CDR3 sequence shown in SEQ ID NO: 89. The CDR1 sequence, CDR2 sequence, and CDR3 sequence shown can form a single domain antibody with framework regions FR of different sources. The framework region FR sequence is not particularly limited and can be of mouse origin, human origin, or partially of mouse origin and partially of human origin.
[0078] SEQ ID NO: Functional area Amino acid sequence 80 CDR1 GRSFSSSG 81 CDR2 INSSGGDT 82 CDR3 AAKEGGGPSSIPAIYDY 83 CDR1 GFTFSSYA 84 CDR2 INTGSEIV 85 CDR3 ATGLVSAEHDGI 86 CDR1 GRDFLTYG 87 CDR2 INWSGSMT 88 CDR3 AARRGAVTYASSNEYEH 89 CDR3 AAKEGGGPSSIPAIFDY
[0079] In some embodiments, the second antigen binding portion has a sequence as shown in SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the sequence of the second antigen binding portion is compared with the amino acid sequence shown in SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99, and the sequence identity is more than 85%, more than 86%, more than 87%, more than 88%, more than 89%, more than 90%, more than 91%, more than 92%, more than 93%, more than 94%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%. The sequences shown in SEQ ID NO: 95, 96, 97, 98, 99 are humanized antibody sequences. The humanized sequences provided have low immunogenicity and high affinity with the target protein.
[0080]
[0081]
[0082]
[0083] The sequence of the second antigen binding portion mentioned above is recorded in the PCT patent application with application number PCT / CN2022 / 110423 and international publication number WO2023 / 011614A, which records that an anti-PD-L1 nano antibody library was obtained by alpaca immunization, and screening and identification were performed to obtain nano antibodies with good affinity, specific binding and tumor killing effects. In this article, the contents recorded in the PCT patent application with application number PCT / CN2022 / 110423 and international publication number WO2023 / 011614A are also cited in whole or in part as needed.
[0084] The present invention also provides a bispecific antibody, comprising: a first antigen binding portion and a second antigen binding portion, wherein the first antigen binding portion can bind to CD73, and the second antigen binding portion can bind to PD-L1.
[0085] According to a specific embodiment, the first antigen binding portion comprises the HCDR sequence shown in SEQ ID NO: 1, 2 and 3 and the LCDR sequence shown in SEQ ID NO: 22, 23 and 24; the second antigen binding portion comprises the CDR1 sequence shown in SEQ ID NO: 80 or 83 or 86, the CDR2 sequence shown in SEQ ID NO: 81 or 84 or 87, and the CDR3 sequence shown in SEQ ID NO: 82 or 85 or 88 or 89. According to a specific embodiment, the first antigen binding portion comprises the HCDR sequence shown in SEQ ID NO: 4, 5 and 6, and the LCDR sequence shown in SEQ ID NO: 22, 23 and 25; the second antigen binding portion comprises the CDR1 sequence shown in SEQ ID NO: 80 or 83 or 86, the CDR2 sequence shown in SEQ ID NO: 81 or 84 or 87, and the CDR3 sequence shown in SEQ ID NO: 82 or 85 or 88 or 89. According to a specific embodiment, the first antigen binding portion comprises the HCDR sequence shown in SEQ ID NO: 7, 8 and 9, and the LCDR sequence shown in SEQ ID NO: 26, 27 and 28; the second antigen binding portion comprises the CDR1 sequence shown in SEQ ID NO: 80 or 83 or 86, the CDR2 sequence shown in SEQ ID NO: 81 or 84 or 87, and the CDR3 sequence shown in SEQ ID NO: 82 or 85 or 88 or 89. According to a specific embodiment, the first antigen binding portion comprises the HCDR sequence shown in SEQ ID NO: 10, 11 and 12, and the LCDR sequence shown in SEQ ID NO: 29, 30 and 31; the second antigen binding portion comprises the CDR1 sequence shown in SEQ ID NO: 80 or 83 or 86, the CDR2 sequence shown in SEQ ID NO: 81 or 84 or 87, and the CDR3 sequence shown in SEQ ID NO: 82 or 85 or 88 or 89. According to a specific embodiment, the first antigen binding portion comprises the HCDR sequence shown in SEQ ID NO: 13, 14 and 15, and the LCDR sequence shown in SEQ ID NO: 22, 23 and 32; the second antigen binding portion comprises the CDR1 sequence shown in SEQ ID NO: 80 or 83 or 86, the CDR2 sequence shown in SEQ ID NO: 81 or 84 or 87, and the CDR3 sequence shown in SEQ ID NO: 82 or 85 or 88 or 89.According to a specific embodiment, the first antigen binding moiety comprises the HCDR sequence shown in SEQ ID NO: 16, 17 and 18, and the LCDR sequence shown in SEQ ID NO: 33, 34 and 35; the second antigen binding moiety comprises the CDR1 sequence shown in SEQ ID NO: 80 or 83 or 86, the CDR2 sequence shown in SEQ ID NO: 81 or 84 or 87, and the CDR3 sequence shown in SEQ ID NO: 82 or 85 or 88 or 89. According to a specific embodiment, the first antigen binding moiety comprises the HCDR sequence shown in SEQ ID NO: 19, 20 and 21, and the LCDR sequence shown in SEQ ID NO: 36, 37 and 38; the second antigen binding moiety comprises the CDR1 sequence shown in SEQ ID NO: 80 or 83 or 86, the CDR2 sequence shown in SEQ ID NO: 81 or 84 or 87, and the CDR3 sequence shown in SEQ ID NO: 82 or 85 or 88 or 89. According to a specific embodiment, the first antigen binding moiety and the second antigen binding moiety are separated by (G4S). 3-5 The linker connects.
[0086] In some embodiments, the first antigen binding moiety comprises the heavy chain variable region of SEQ ID NO:39, and the light chain variable region of SEQ ID NO:46; the second antigen binding moiety comprises the sequence of SEQ ID NO:90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding moiety comprises the heavy chain variable region of SEQ ID NO:40, and the light chain variable region of SEQ ID NO:47; the second antigen binding moiety comprises the sequence of SEQ ID NO:90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding moiety comprises the heavy chain variable region of SEQ ID NO:41 and the light chain variable region of SEQ ID NO:48; the second antigen binding moiety comprises the sequence of SEQ ID NO:90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding moiety comprises the heavy chain variable region of SEQ ID NO:42 and the light chain variable region of SEQ ID NO:49; the second antigen binding moiety comprises the sequence of SEQ ID NO:90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding moiety comprises the heavy chain variable region of SEQ ID NO:43 and the light chain variable region of SEQ ID NO:50; the second antigen binding moiety comprises the sequence of SEQ ID NO:90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding moiety comprises the heavy chain variable region of SEQ ID NO:44 and the light chain variable region of SEQ ID NO:51; the second antigen binding moiety comprises the sequence of SEQ ID NO:90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding moiety comprises the heavy chain variable region shown in SEQ ID NO: 45 and the light chain variable region shown in SEQ ID NO: 52; the second antigen binding moiety comprises the sequence shown in SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding moiety comprises the heavy chain variable region shown in SEQ ID NO: 53 and the light chain variable region shown in SEQ ID NO: 66; the second antigen binding moiety comprises the sequence shown in SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99.In some embodiments, the first antigen binding portion comprises the heavy chain variable region of SEQ ID NO: 54 and the light chain variable region of SEQ ID NO: 67; the second antigen binding portion comprises the sequence of SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises the heavy chain variable region of SEQ ID NO: 55 and the light chain variable region of SEQ ID NO: 68; the second antigen binding portion comprises the sequence of SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises the heavy chain variable region of SEQ ID NO: 56 and the light chain variable region of SEQ ID NO: 69; the second antigen binding portion comprises the sequence of SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises the heavy chain variable region of SEQ ID NO: 57 and the light chain variable region of SEQ ID NO: 70; the second antigen binding portion comprises the sequence of SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises the heavy chain variable region of SEQ ID NO: 58 and the light chain variable region of SEQ ID NO: 71; the second antigen binding portion comprises the sequence of SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises the heavy chain variable region of SEQ ID NO: 59 and the light chain variable region of SEQ ID NO: 72; the second antigen binding portion comprises the sequence of SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises the heavy chain variable region shown in SEQ ID NO: 60 and the light chain variable region shown in SEQ ID NO: 73; the second antigen binding portion comprises the sequence shown in SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises the heavy chain variable region shown in SEQ ID NO: 60 and the light chain variable region shown in SEQ ID NO: 74; the second antigen binding portion comprises the sequence shown in SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99.In some embodiments, the first antigen binding portion comprises the heavy chain variable region of SEQ ID NO: 61 and the light chain variable region of SEQ ID NO: 75; the second antigen binding portion comprises the sequence of SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises the heavy chain variable region of SEQ ID NO: 62 and the light chain variable region of SEQ ID NO: 76; the second antigen binding portion comprises the sequence of SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises the heavy chain variable region of SEQ ID NO: 63 and the light chain variable region of SEQ ID NO: 77; the second antigen binding portion comprises the sequence of SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding moiety comprises the heavy chain variable region shown in SEQ ID NO: 64 and the light chain variable region shown in SEQ ID NO: 78; the second antigen binding moiety comprises the sequence shown in SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding moiety comprises the heavy chain variable region shown in SEQ ID NO: 65 and the light chain variable region shown in SEQ ID NO: 79; the second antigen binding moiety comprises the sequence shown in SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. According to a specific embodiment, the first antigen binding moiety and the second antigen binding moiety are separated by (G4S). 3-5 The linker connects.
[0087] According to a specific embodiment, the heavy chain variable region of the first antigen binding moiety is connected to the heavy chain constant domain, and the light chain variable region of the first antigen binding moiety is connected to the light chain constant domain to form an IgG type structure. In addition to the heavy chain variable region and light chain variable region sequences mentioned, the other sequences of the formed IgG type structure can adopt natural sequences of mammalian origin (for example, natural sequences of human origin). According to a specific embodiment, the second antigen binding moiety is connected to the carboxyl end (C-terminus) of the Fc region; or the second antigen binding moiety is connected to the amino end (N-terminus) of the heavy chain variable region or the light chain variable region of the first antigen binding moiety; or the second antigen binding moiety is connected to the carboxyl end (C-terminus) of the light chain constant domain CL.
[0088] The Fc region mentioned can be a natural Fc region sequence or a modified Fc region sequence, for example, the sequence of the Fc region can be mutated. The ADCC (antibody-dependent cell-mediated cytotoxicity), ADCP (antibody-dependent cell-mediated phagocytosis) or CDC (complement-mediated cytotoxicity) of the antibody can be regulated by mutation of the Fc region. ADCC refers to the binding of the Fab segment of the antibody to the antigenic epitope of virus-infected cells or tumor cells, and the binding of its Fc segment to the Fc receptor (FcR) on the surface of killer cells (such as NK cells, macrophages, etc.), mediating the direct killing of target cells by killer cells. ADCP mainly engulfs target cells through the mediation of monocytes, macrophages, neutrophils and dendritic cells. CDC is formed by the binding of antibodies to the corresponding antigens on the cell membrane surface to form a complex to activate the classical complement pathway and exert a lytic effect on target cells. The mutation of the Fc region sequence can be one, two, three, four or five amino acid mutations. Of course, in addition to the amino acid mutations in the Fc region, mutations may also occur in other regions, such as the heavy chain constant domain CH1, hinge region, etc. The amino acid mutations mentioned are known to those skilled in the art, including but not limited to L234F, L234A, L235E, G236R, G237A, D270A, K322A, P329A, P331S, P331A, N297A, N297G, A330S, V309L, P238S, G236R, L328R, etc. The amino acid mutation mentioned can also be L235V, R292P, K326W, E333S, S267E, H268F, S324T, F243L, R292P, Y300L, V305L, V305I, P396L, S239D, I332E, A330L, S298A, E333A, K334A etc. The amino acid mutation mentioned can be selected from these mutation sites, or the combination of several mutation sites. In some embodiments, A330S and P331S replace in the bispecific antibody provided. In some embodiments, D270A, K322A, P329A and P331A replace in the bispecific antibody provided. In some embodiments, L234F, L235E, P331S and N297A replace in the bispecific antibody provided. In some embodiments, the provided bispecific antibodies have S267E, H268F and S324T mutations. In some embodiments, the provided bispecific antibodies have K214R, L234F, L235E, P331S, D356E and L358M mutations. Of course, the half-life of antibody drugs can also be improved by modifying the Fc region sequence, and the available amino acid mutation sites are also known to those skilled in the art.The numbering of mutation sites in this article is based on the EU index proposed by Kabat (Kabat, EA et al., Sequences of Proteins of Immunological Interest. 5. th Edition-USDepartment of Health and human services,NIHpublication n 91-3242,pp662,680,689(1991)).
[0089] Polynucleotide
[0090] The present invention also provides a polynucleotide encoding an antibody or an antigen-binding fragment or a bispecific antibody. The polynucleotide mentioned is separable, including but not limited to DNA, RNA or cDNA, etc. The isolated polynucleotide sequence can be obtained by conventional methods in the art to encode a bispecific antibody or an antibody or an antigen-binding fragment.
[0091] Constructs
[0092] In order to prepare the antibodies mentioned in the present invention, the polynucleotide sequence encoding the antibody can be inserted into a replicable expression vector and expressed in a host cell or a cell-free expression system. The present invention also provides a construct comprising the polynucleotide described above. A variety of methods commonly used in the art can be used to obtain the construct, including in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, etc. For example, the polynucleotide can be inserted into the multiple cloning site of the expression vector to form a construct. The construct can contain a variety of operating factors such as promoters, terminators, marker genes, etc. as needed, and these operating factors can be operably connected to the polynucleotide. The promoter is usually used to provide a signal to start transcription. The promoter can select lactose promoter (Lac), Trp promoter, Tac promoter, phage PL and PR promoter as needed; the terminator provides a signal for transcription termination during the transcription process, and the marker gene on the construct is often used for screening. Of course, there can also be enhancers as needed to enhance protein expression. The expression vector is not particularly limited, and can be some commercially available expression vectors, or it can be an expression vector artificially modified as needed, such as a plasmid, a phage, a virus, etc. The virus can be a plant cell virus, a mammalian cell virus, etc. The construct can express antibodies or proteins in vitro or be introduced into cells to express antibodies or proteins.
[0093] Host cells
[0094] The present invention also provides a host cell containing the above-mentioned polynucleotide or the above-mentioned construct. Any cell suitable for expressing antibodies or proteins with polynucleotides or constructs can be used as a host cell. The host cell can be a prokaryotic cell, such as a bacterial cell; or a eukaryotic cell, such as a yeast cell, a mammalian cell, etc. Commonly used host cells can be yeast cells, CHO, HEK-293 cells, COS cells, insect cells of Drosophila S2 or Sf9. Host cells containing polynucleotides or constructs can be obtained by methods commonly used in the art, such as microinjection, electroporation, chemical transfection, virus-mediated transformation, etc.
[0095] Pharmaceutical composition
[0096] The present invention also provides a pharmaceutical composition, comprising: the above-mentioned antibody or antigen-binding fragment, or the above-mentioned bispecific antibody, and a pharmaceutically acceptable carrier.
[0097] The pharmaceutical composition also includes a pharmaceutically acceptable salt, such as an acid addition salt or a base addition salt (e.g., as described in Berge, S. M. et al (1977) J. Pharma. Sci. 66: 1-19). The pharmaceutically acceptable carrier mentioned is acceptable to the subject at the dose or concentration used. Pharmaceutically acceptable carriers include, but are not limited to, buffers or salts, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, sodium acetate, citric acid, sodium citrate, citrate, Tris; sugars, such as trehalose, polysorbate, sucrose, mannitol; surfactants such as polysorbate; preservatives such as hexamethonium chloride, benzalkonium chloride, benzethonium chloride; amino acids such as histidine, histidine hydrochloride, glycine, glutamine, asparagine, arginine or lysine, etc. Sterile pharmaceutical preparations can be obtained by methods commonly used in the art, such as by filtering with a sterile filter membrane. Those skilled in the art can select different pharmaceutically acceptable carriers for the pharmaceutical composition as needed to prepare different dosage forms, such as freeze-dried dosage forms, injections, etc. The prepared different pharmaceutical dosage forms can be formulated into any suitable administration route for administration to the subject, including but not limited to intravenous, dermal, intramuscular, peritoneal, subcutaneous, nasal, oral, rectal, topical, inhalation, transdermal, etc.
[0098] In addition to the above, the pharmaceutical composition mentioned may further include other therapeutic agents. The therapeutic agent mentioned is a substance that can exert a therapeutic effect. For example, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, anti-TIM-3 antibodies, anti-LAG-3 antibodies, anti-VEGF antibodies, anti-EGFR antibodies, anti-GARP antibodies, anti-CD3 antibodies, anti-TIGIT antibodies, anti-OX40 antibodies, anti-TGF-β antibodies, etc. By combining with these therapeutic antibodies, the therapeutic effect of the disease can be further improved, thereby effectively treating a variety of diseases.
[0099] Antibody Conjugates
[0100] The present invention also provides an antibody conjugate, the antibody conjugate includes the bispecific antibody or antibody or antigen binding fragment, and a functional small molecule or protease connected to the bispecific antibody or antibody or antigen binding fragment. The functional small molecule mentioned can be a developed or undeveloped small molecule drug, which is chemically coupled with the bispecific antibody or monoclonal antibody or antigen binding fragment to enhance the therapeutic effect of anti-tumor drugs and reduce adverse reactions. Small molecules such as toxins, chemotherapeutics, and photosensitizers can also be coupled to the antibodies mentioned by a connector. Of course, an antibody Protac conjugate can also be obtained by coupling an antibody with a protac molecule, such as connecting an antibody and a protease targeting ligand (such as an E3 ligase ligand) by a connector, closing the distance between the target protein and the E3 ubiquitin ligase in the cell, and utilizing the ubiquitin-proteasome pathway to specifically degrade the target protein.
[0101] Test kit or medicine box
[0102] The present invention also provides a kit, which includes the above-mentioned bispecific antibody or the above-mentioned monoclonal antibody or antigen-binding fragment. The kit may also include containers, buffer reagents, and controls such as positive controls and negative controls as needed. Those skilled in the art can make corresponding choices as needed. Accordingly, the kit may also include instructions for use to facilitate the operation and use of those skilled in the art. In some embodiments, the present invention also provides a drug kit, which includes the above-mentioned anti-CD73 antibody or antigen-binding fragment, or includes the above-mentioned bispecific antibody. The drug kit may further include an immunotherapeutic agent, wherein the immunotherapeutic agent is one or more of a variety of therapeutic antibodies such as anti-PD-L1 antibodies, anti-PD-1 antibodies, or anti-CTLA-4 antibodies. The anti-PD-L1 antibodies, anti-PD-1 antibodies, or CTLA-4 antibodies mentioned are drugs that have been marketed, disclosed in the literature, or will be marketed in the future.
[0103] Methods for producing antibodies
[0104] The present invention further provides a method for producing the above-mentioned bispecific antibody, comprising: culturing the above-mentioned host cell, and collecting the bispecific antibody from the culture.
[0105] The present invention also provides a method for producing an antibody or an antigen-binding fragment, comprising: culturing the above host cell, and collecting the antibody or antigen-binding fragment from the culture.
[0106] The bispecific antibody or monoclonal antibody or antigen-binding fragment collected from the culture can be purified to obtain a substantially pure product. "Substantially pure" means that the purity of the bispecific antibody or monoclonal antibody or antigen-binding fragment is greater than 95%, greater than 96%, greater than 97%, greater than 98%, greater than 99%, or even greater than 99.5%, 99.6%, 99.7%, or 99.8%.
[0107] Methods of preventing and / or treating disease
[0108] In addition, the present invention provides a method for preventing and / or treating a disease, comprising: administering an effective amount of the above-mentioned bispecific antibody, or the above-mentioned antibody or antigen-binding fragment to a subject in need.
[0109] The "treatment" mentioned here means that it can lead to a reduction in the severity of disease symptoms, an increase in the frequency and duration of asymptomatic periods of the disease, or a reduction in the pain caused by the disease. The effective amount of antibodies used to prevent diseases is usually lower than the effective amount of antibodies used to treat diseases. "Effective amount" is an amount sufficient to achieve or at least partially achieve the desired effect. After treatment with a bispecific antibody or a monoclonal antibody or an antigen-binding fragment, the inhibition rate of cells in the subject's body reaches 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, or even 90% or more or 95% or more. The subject mentioned here can be an animal or a human. For example, it can be a mammal, including cattle, sheep, mice, horses, etc.
[0110] The provided bispecific antibodies or monoclonal antibodies or antigen-binding fragments thereof can be used to treat diseases including but not limited to cancer, inflammatory diseases, chronic infections, cardiovascular and cerebrovascular diseases, fibrosis, neurodegenerative diseases, immunomodulatory diseases, central nervous system diseases and diabetes, etc. In some embodiments, the methods provided by the present invention can be used to treat CD73 target-related diseases, and can also be used to treat PD-1 / PD-L1-related diseases. The cancers mentioned include but are not limited to non-small cell lung cancer, small cell lung cancer, squamous cell carcinoma, glioma, colon cancer, kidney cancer, urothelial carcinoma, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, gastrointestinal cancer, esophageal cancer, prostate cancer, cervical cancer, uterine cancer, head and neck cancer, adrenal cancer, urethral cancer, vaginal cancer, bladder cancer, melanoma and blood cancer, etc. In some embodiments, the diseases mentioned are non-small cell lung cancer and melanoma.
[0111] The antibody or antigen-binding fragment or bispecific antibody mentioned above can also be combined with other treatment methods to treat diseases. The other treatment methods mentioned above can be chemotherapy or radiotherapy. By combining chemotherapy or radiotherapy and other treatment methods clinically, the therapeutic effect of the drug can be further improved, and the treatment effect of the patient can be improved.
[0112] The present invention also provides the use of a bispecific antibody or a monoclonal antibody or an antigen-binding fragment in preparing a drug or a kit. The drug is used to treat cancer. The provided bispecific antibody or monoclonal antibody or antigen-binding fragment can be used to prepare a drug for treating a variety of diseases. It can also be used to prepare a kit for use as an immunodiagnostic reagent.
[0113] The technical scheme of the present invention is described in detail with reference to the embodiments below. It should be noted that these embodiments are only used to facilitate the understanding of those skilled in the art and should not be regarded as limiting the scope of protection of the present invention. The embodiments of the present invention are described in detail below. The described embodiments are exemplary and are intended to be used to explain the present invention, and cannot be understood as limiting the present invention. The PD-L1 binding portion derived from the second antigen binding portion is a nanobody obtained by immunization of alpaca, and its sequence preparation and acquisition method are recorded in the text of the PCT international patent application with application number PCT / CN2022 / 110423 and international publication number WO2023 / 011614A. The contents recorded in the application are all or partly cited in the present application as needed. First, an anti-PD-L1 nano library is obtained by alpaca immunization, and the candidate nano antibodies are obtained by screening and identification. Specifically, the fusion protein consisting of the extracellular domain sequence of the human PD-L1 protein and the Fc region sequence of the human immunoglobulin is mixed with Freund's adjuvant, emulsified, and immunized with healthy alpacas to stimulate B cells to express antigen-specific nanobodies. Then, alpaca blood was collected, lymphocytes were separated, total RNA was extracted by Trizol method, cDNA was obtained by reverse transcription, and VHH antibody gene fragments were obtained from the reverse transcribed cDNA by PCR amplification. The VHH gene fragment and the yeast display vector were co-transformed into competent yeast, and the yeast homologous recombination enzyme connected the fragment to the vector to form a complete plasmid, and a yeast transformant library with high library insertion rate and excellent diversity was established, and the passage was kept stable in the nutrient-deficient medium. The yeast cells expressing the antibody were co-incubated with magnetic beads enriched with target protein antigens, and after multiple enrichment cultures, the magnetic bead enrichment products were identified by flow cytometry and sorted. After multiple rounds of screening, 5 highly expressed positive clones were screened and named antibody A to antibody E. The amino acid sequence of antibody A is shown in SEQ ID NO:90, the amino acid sequence of antibody B is shown in SEQ ID NO:91, the amino acid sequence of antibody C is shown in SEQ ID NO:92, the amino acid sequence of antibody D is shown in SEQ ID NO:93, and the amino acid sequence of antibody E is shown in SEQID NO:94. The humanized antibodies are antibody Ahu, whose amino acid sequence is shown in SEQ ID NO:95; antibody Bhu, whose amino acid sequence is shown in SEQ ID NO:96; antibody Chu, whose amino acid sequence is shown in SEQ ID NO:97; antibody D1hu, whose amino acid sequence is shown in SEQ ID NO:98; and antibody D2hu, whose amino acid sequence is shown in SEQ ID NO:99.
[0114] These antibodies and humanized antibodies have been confirmed by FACS and ELISA experiments to have high binding activity with hPD-L1 and cynomolgus monkey PD-L1, and show blocking activity for PD-1 / PD-L1 and CD80 / PD-L1.
[0115] For example, the binding activity of antibodies and human PD-L1 is detected by FACS. The experimental process is as follows: the affinity of different antibodies and antigens is detected by flow cytometry. MDA-MB-231 cells endogenously expressing PD-L1 antigen are cultured at 1×10 5 Each well was added to a 96-well plate. Then, samples of different concentrations were added and incubated at 4 degrees Celsius for 30 minutes. Then, a fluorescently labeled goat anti-human IgG secondary antibody (manufacturer: Abcam) was added to detect antibodies bound to the cell surface. The antibody-antigen binding dose-response curve was generated using geometric values, and the original data of the four parameters were plotted using Graphpad Prism V6.0 software to determine the EC50 results of antibody binding to antigen. The experimental results showed that the EC50 values of antibody A, antibody B, antibody C, antibody D, and antibody E were 0.089nM, 0.031nM, 0.042nM, 0.039nM, and 0.053nM, respectively, which were similar to the positive control (atezolizumab, 0.059nM), showing high binding activity. A similar method was used to determine the binding activity of humanized antibodies, and the EC50 values of antibody Ahu, antibody Bhu, antibody Chu, antibody D1hu, and antibody D2hu were 0.051 nM, 0.18 nM, 0.023 M, 0.18 nM, and 0.29 nM, respectively.
[0116] Another example is to measure the blocking activity of antibodies against PD-1 / PD-L1 by FACS. The experimental process is: using a competitive flow cytometry method to detect the blocking effect of antibodies on PD-1 and its ligand PD-L1. Resuscitate the 293T-PD-1 cell line overexpressing PD-1 (manufacturer: Kangyuan Bochuang Biotechnology (Beijing) Co., Ltd.), and the cells are plated at 1×10 5100ul / well were plated in a 96-well plate, and different concentrations of antibody diluent (starting working concentration was 200nM, 4-fold dilution) and PD-L1-Biotin diluent (2ug / ml, 50ul / well) were mixed and incubated at room temperature for 30 minutes. Then the mixture was added to the cells at 100ul per well, mixed, incubated at 4 degrees Celsius for 60 minutes, then washed with FACS buffer (PBS containing 2% FBS), centrifuged at 1200rpm for 4 minutes, and the supernatant was discarded. PE-labeled streptavidin was added at 100ul / well, incubated in the dark for 30 minutes, and washed with FACS buffer after the incubation. Add 120ul of FACS buffer to resuspend the cells and detect them on the machine. Shoot the live cells according to FSC / SSC and measure their average fluorescence values. The antibody-antigen blocking reaction curve was generated using geometric values, and the four-parameter graph was drawn using GraphpadPrism V6.0 software to determine the IC50 value. The experimental results showed that the IC50 values of antibody A, antibody B, antibody C, antibody D and antibody E were 1.0nM, 2.1nM, 1.7nM, 2.1nM and 2.5nM, respectively, and all antibodies could block the binding between antigen and its ligand. The blocking activity of humanized antibodies was determined by a similar method, and the IC50 values of antibody Ahu, antibody Bhu, antibody Chu, antibody D1hu and antibody D2hu were 4.0nM, 3.4nM, 1.0nM, 2.6nM and 12nM, respectively.
[0117] The blocking activity of the antibody on CD-80 / PD-L1 was determined by FACS. The experimental process was as follows: a competitive flow cytometry-based method was used to detect the blocking effect of the antibody on PD-L1 and CD-80. The 293T-PD-L1 cell line overexpressing PD-L1 (manufacturer: Kangyuan Bochuang Biotechnology (Beijing) Co., Ltd.) was revived and the cells were plated at 1×10 5Each well was plated in a 96-well plate, and different concentrations of antibody dilutions (starting working concentration was 200nM, 4-fold dilution) were added to the cells and incubated at 4°C for 60 minutes. After incubation, the cells were washed with FACS buffer, centrifuged at 1200rpm for 4 minutes, and the supernatant was discarded. Then human-CD80-mFc (2ug / ml) was added at 100ul / well and incubated at 4°C in the dark for 30 minutes. After incubation, the cells were washed with FACS buffer. 100ul of 1:200 diluted fluorescently labeled goat anti-mouse secondary antibody (manufacturer: Abcam) was added to each well and incubated at 4°C in the dark for 30 minutes. After incubation, the cells were washed with FACS buffer and detected by flow cytometry. The average fluorescence value was measured. The antibody-antigen blocking reaction curve was generated using geometric values, and a four-parameter graph was drawn using Graphpad Prism V6.0 software to determine the IC50 value. The experimental results showed that the IC50 values of antibody A, antibody B, antibody C, antibody D and antibody E were 4.0nM, 3.4nM, 4.1nM, 4.8nM and 3.0nM, respectively, and all antibodies could block the binding of antigen and its ligand. The blocking activity of humanized antibodies was determined by a similar method, and the IC50 values of antibody Ahu, antibody Bhu, antibody Chu and antibody D1hu were approximately 1.8nM, 1.7nM, 3.2nM and 1.5nM, respectively.
[0118] Example 1 Preparation of monoclonal antibodies
[0119] Mice were immunized with CD73 antigen, and monoclonal antibodies were obtained by hybridoma screening. Mouse myeloma cells and mouse spleen cells were fused and the fused cells were plated. Then HAT selective medium was added for screening. Myeloma cells could not survive, and spleen cells had a short survival time. In the end, only myeloma cells fused with lymphocytes survived, that is, hybridoma cells were screened.
[0120] Then, the hybridoma cells that can produce specific antibodies are selected by the method of limiting dilution cloning cells. The hybridoma cells are diluted multiple times and inoculated on a porous cell culture plate so that there is no more than one cell in each well. The cells are cultured and proliferated. When the clones grow to a certain size, the antibodies secreted by the cells in the supernatant of each well are detected by ELISA. The culture wells that can bind to the specific antigen (CD73) are positive wells, and the dilution is continued until monoclonal cells are obtained.
[0121] By the above method, multiple positive clones were screened and differentially screened to obtain 7 clones with high activity, which were numbered as clone309, clone307, clone144, clone235, clone451, clone540, and clone449. All 7 clones obtained showed high affinity to human CD73 antigen and high enzyme activity blocking activity.
[0122] The selected clones were sequenced, and the variable regions of the selected clones were fused with the constant region sequences of human origin and constructed into the PCDNA3.1 mammalian expression vector to construct chimeric antibodies. The obtained different antibodies were then expressed and purified using a mammalian cell system to obtain different antibodies with a purity of at least 90%. The expressed antibodies were numbered mab309, mab307, mab144, mab235, mab451, mab540 and mab449.
[0123] Example 2 Identification of Antibody Binding Activity to CD73
[0124] Use human CD73 (hCD73, manufacturer: ACRO) to coat the ELISA plate, 100ng / well, incubate overnight at 4℃. Then wash with PBST, add 200ul 2% BSA to each well, and block at 37℃ for 1h. Wash with PBST, and add different concentrations of the test antibody at 100uL / well (the initial concentration of each antibody is 31.25nM, 4-fold gradient dilution), and incubate at 37℃ for 2h. Wash with PBST, and add goat anti-human secondary antibody (1% BSA dilution, 1:10000, manufacturer: Jackson) at 100uL / well, and incubate at 37℃ for 1h. Wash with PBST, add 100ul TMB colorimetric solution for 10-15min, and then add 50ul2M sulfuric acid to terminate the reaction. The OD450 value was read using a microplate reader, and the EC50 value of the antibody to be tested was calculated using the data processing software Graphpad Prism 8.0, as shown in Table 1 below, where the positive control was the anti-CD73 antibody olecumab (MEDI9447) from Medimune, a subsidiary of AstraZeneca. The same positive control was used in the following examples.
[0125] Table 1
[0126]
[0127] The experimental results show that all the antibodies shown can specifically bind to CD73.
[0128] Example 2 Antibody Binding Activity to MDA-MB-231 Cells
[0129] CD73 antigen is highly expressed on the surface of MDA-MB-231 cells. FACS was used to detect the binding activity of the antibody to MDA-MB-231 cells. MDA-MB-231 cells were cultured and the cell concentration was adjusted to 1-2×10 6 / ml, and then added to a 96-well plate at 100ul / well. Centrifuge at 1000rpm for 5min, discard the culture supernatant, and then add different test antibodies at 100ul / well (initial antibody concentration is 200nM, 4-fold gradient dilution), and incubate at 4℃ for 30min. Wash with buffer, add fluorescently labeled goat anti-human secondary antibody (manufacturer: Abcam), and incubate at 4℃ for 30min. Wash the cells twice with buffer, add buffer to resuspend the cells, and detect the fluorescence signal on the flow cytometer. The EC50 value of the test sample was calculated using the data processing software Graphpad Prism8.0, as shown in Table 2 below.
[0130] Table 2
[0131]
[0132]
[0133] From the results in Table 2, it can be seen that all antibodies can bind to human CD73 and show properties similar to those of the positive control.
[0134] Example 3 Antibodies Cross-React with Monkey CD73
[0135] Use monkey CD73 (CynoCD73, manufacturer: ACRO) to coat the ELISA plate, 100ng / well, incubate overnight at 4°C. Then wash with PBST, add 200ul 2% BSA to each well, and block at 37°C for 1h. Wash with PBST, and add different concentrations of the antibody to be tested (the initial concentration of the antibody is 31.25nM, 4-fold gradient dilution) at 100uL / well, and incubate at 37°C for 2h. Wash with PBST, and add goat anti-human secondary antibody (1% BSA dilution, manufacturer: Jackson) at 100uL / well, and incubate at 37°C for 1h. Wash with PBST, add 100ul TMB colorimetric solution for 10-15min, and then add 50ul 2M sulfuric acid to terminate the reaction. The OD450 value was read using an ELISA instrument, and the EC50 value of the antibody to be tested was calculated using the data processing software Graphpad Prism8.0, as shown in Table 3 below.
[0136] Table 3
[0137] Antibody ID EC50(nM) mab309 0.028 mab307 0.013 mab144 0.027 mab235 0.020 mab451 0.024 mab540 0.041 mab449 0.030 hIgG1 No combination Positive Control 0.023
[0138] The experimental results showed that the listed antibodies all exhibited binding activity with cynoCD73.
[0139] Example 4 Antibody enzyme activity blocking experiment
[0140] MDA-MB-231 tumor cells were cultured in DMEM + 10% FBS + 1% PS. The cells were digested and resuspended for counting, and the cell density was adjusted to 4.5 × 10 5 / mL, spread in 96-well cell culture plates at 100ul / well. Dilute the antibody to be tested with culture medium (initial concentration is 200nM, 4-fold gradient dilution). After dilution and mixing, add 50uL / well to the cell culture plate, incubate in a 37℃, 5% CO2 incubator for 1h, and add 50uL 0.8mM AMP (manufacturer: Sigma) to each well. After mixing, place in a 37℃, 5% CO2 incubator for 2h. Centrifuge at 1000rpm for 5min, and take 50uL supernatant and place in a new 96-well plate. Add 50uL 130uM ATP (manufacturer: Sigma) to each well. After mixing, add 100ul Cell titer glo detection reagent (manufacturer: Promega) to each well and incubate in the dark for 5-10 minutes. Use an enzyme reader to read the fluorescence signal in the 96-well plate. Use the relative fluorescence value as the y-axis and the concentration of the antibody sample as the x-axis to draw a four-parameter curve. The curve was analyzed using GraphPad Prism 8.0 software and the IC50 value of the antibody was obtained.
[0141] Table 4
[0142] Antibody ID IC50(nM) mab144 0.30 mab235 0.22 mab451 0.25 mab540 0.18 mab449 0.15 hIgG1 Not blocked
[0143] The experimental results showed that mab144 antibody, mab235 antibody, mab451 antibody, mab540 antibody, and mab449 antibody all exhibited enzyme blocking activity, which was similar to that of the positive control.
[0144] Example 5 Antibody endocytosis experiment
[0145] MDA-MB-231 tumor cells were cultured, digested with 0.25% trypsin, resuspended and counted, and the cell density was adjusted to 1×10 6 / mL, spread in 96-well culture plates at 100ul / well. Centrifuge at 1000rpm for 5 minutes and discard the supernatant. Dilute the antibody to be tested to 20nM with FACS buffer, then add 100uL / well to the 96-well plate, mix with the cells and place in a 4℃ refrigerator for 30 minutes. Then centrifuge at 1000rpm for 10min and wash with FACS buffer. One of the samples is marked as 0h, placed on ice and temporarily stored in a 4℃ refrigerator, and the other samples are placed in a 37℃ constant temperature incubator for 4h. Then take out the 0h sample on ice and the 37℃ 4h sample, centrifuge and discard the supernatant, add 100ul goat anti-human fluorescent secondary antibody (1:200 dilution, Abcam) and mix well, and place in a 4℃ refrigerator for 30min. Then wash with FACS buffer. Add buffer to resuspend the cells and detect the fluorescence signal on the flow cytometer. Calculate the antibody internalization ratio based on the read fluorescence signal, and the calculation formula is:
[0146] Internalization ratio (%) = (0h fluorescence signal - 4h fluorescence signal) / 0h fluorescence signal * 100%.
[0147] The experimental results are as follows Figure 6 The results showed that anti-CD73 antibodies could promote the internalization of CD73.
[0148] Example 6 Antitumor efficacy of antibodies
[0149] CT26-hPDL1-hCD73 cells were cultured to the logarithmic growth phase, the cells were collected, the culture medium was removed and washed with PBS, and then inoculated into BALB / C-hPD1 / hPDL1 / hCD73 triple transgenic mice (humanized mouse model expressing human PD1, human PDL1 extracellular domain protein and human CD73 protein, manufacturer: Jiangsu Jicui Pharmaceutical Kang Biotechnology Co., Ltd.), with an inoculation size of 1×10 6 cells / 100μL / mouse. When the average tumor volume reaches 80-120mm 3 When the mice were about 40 μg / kg, they were randomly divided into 10 groups, with 6 mice in each group. The day of grouping was defined as D0, and anti-PD-L1 antibody (antibody number D2hu, dosing concentration of 1.5 mpk (mg / kg)) and anti-CD73 antibody (dosing concentration of 10 mpk) were co-administered on D0, twice a week for two weeks, by intraperitoneal injection, and the coefficient of variation CV of tumor volume did not exceed 1 / 3. After administration, tumor volume and mouse weight were measured 2-3 times a week according to tumor growth. Tumor volume calculation method is: tumor volume (mm 3 ) = 0.5 × long diameter of tumor × short diameter of tumor 2 The experimental results are as follows Figure 7As shown. G1 is PBS, G2 is anti-PD-L1 antibody administration (administration concentration is 1.5 mpk), G3 is anti-PD-L1 antibody and mab307 antibody co-administration, G4 is anti-PD-L1 antibody and mab309 antibody co-administration, G5 is anti-PD-L1 antibody and mab235 antibody co-administration, G6 is anti-PD-L1 antibody and mab540 antibody co-administration, G7 is anti-PD-L1 antibody and mab144 antibody co-administration, G8 is anti-PD-L1 antibody and mab449 antibody co-administration, G9 is anti-PD-L1 antibody and mab451 antibody co-administration.
[0150] The results showed that the anti-tumor efficacy of mab309 antibody, mab307 antibody, mab235 antibody, mab540 antibody, mab144 antibody, mab449 antibody, and mab451 antibody combined with PD-L1 antibody in mice was better than that of PD-L1 antibody alone.
[0151] Example 7
[0152] The complementary determining region transplantation method (CDR-Grafting method) is used to obtain humanized antibodies. The amino acid sequences of the antibody and the template are uniformly divided into FR regions and CDR regions, and then the CDR regions are transplanted to the FR regions of the template, so that the CDR regions that determine the specificity of the antibody and the framework regions of the humanized antibody are combined with each other to achieve the purpose of humanization. At the same time, in order to avoid the decrease in antibody affinity, the key amino acid residue sites are calculated by computer simulation and other technologies, and the affinity of the humanized antibody is ensured by the method of reverse mutation. The humanized antibodies of the above antibodies are obtained. When the humanized antibodies are named, the letters "hu" are added after the antibody number, and different numbers are added to represent different humanized antibodies. In addition, the Fc region of the humanized antibody is mutated, and the letters "mu" are added as a suffix when the mutated antibodies are named. One of the mutations includes L234F, L235E, P331S and N297A mutations, and the letters "mu1" are added as a suffix when the mutated antibodies are named. Another type of mutation includes K214R, L234F, L235E, P331S, D356E and L358M mutations. The letters "mu2" are added as the suffix in the name of the mutated antibody. For example, mab309hu1 indicates the first antibody of mab309 antibody after humanization. mab144hu2 indicates the second antibody of mab144 antibody after humanization. mab309hu3mu indicates the third antibody of mab309 antibody after humanization, and the Fc region of the antibody has also mutated.
[0153] Example 8 Humanized Antibody Binding Activity to MDA-MB-231 Cells
[0154] CD73 antigen is highly expressed on the surface of MDA-MB-231 cells. MDA-MB-231 cells were added into a 96-well plate at 100ul / well, and the cell concentration was 1-2×10 6 / ml. Wash with FACS buffer (i.e. PBS solution containing 2% FBS), then add different antibodies to be tested (initial antibody concentration is 200nM, 4-fold gradient dilution) at 100ul / well, and incubate at 4°C for 30min. Wash with buffer, add fluorescently labeled goat anti-human secondary antibody (manufacturer: Abcam), and incubate at 4°C for 30min. Wash the cells twice with buffer, add buffer to resuspend the cells, and detect the fluorescence signal on the flow cytometer. Use the data processing software GraphpadPrism8.0 to calculate the EC50 value of the sample to be tested, as shown in Table 5 below.
[0155] Table 5
[0156] Antibody ID EC50(nM) mab309hu1mu1 1.1 mab309hu3mu1 3.0 mab144hu2mu1 1.5 mab451hu4mu1 0.68 mab451hu5mu1 0.88 mab451hu6mu1 0.73 mab540hu1mu1 1.3 mab540hu3mu1 0.87 mab449hu4mu1 0.53 Positive Control 0.55 hIgG1 No combination
[0157] The humanized antibody showed high binding activity to MDA-MB-231 cells, similar to the positive control.
[0158] Example 9 Humanized Antibody Enzyme Blocking Activity
[0159] Culture A375 tumor cells, digest the cells with 0.25% trypsin, and adjust the cell density to 4.5 × 10 5 / mL, spread in 96-well cell culture plates at 100ul / well. Dilute different antibodies to be tested with culture medium (initial concentration is 200nM, 4-fold gradient dilution). After dilution and mixing, add 50uL / well to the cell culture plate, incubate in a 37℃, 5% CO2 incubator for 1h, and add 50uL 0.8mM AMP (manufacturer: Sigma) to each well. After mixing, incubate in a 37℃, 5% CO2 incubator for 2h. Centrifuge at 1000rpm for 5min, aspirate 50uL supernatant to a new 96-well cell culture plate, and add 50uL 130uM ATP (manufacturer: Sigma) to each well. After mixing, add 100ul Cell titer glo detection reagent (manufacturer: Promega) to each well. Incubate in the dark for 5-10 minutes, and read the fluorescence signal in the 96-well plate with an enzyme reader. Use the relative fluorescence value as the y-axis and the concentration of the antibody sample as the x-axis to draw a four-parameter curve. The curve was analyzed using GraphPad Prism 8.0 software and the IC50 values of the antibodies were obtained, as shown in Table 6 below.
[0160] Table 6
[0161] Antibody ID IC50(nM) mab144hu1mu1 0.087 mab144hu2mu1 0.055 mab449hu4mu1 0.061 mab451hu4mu1 0.072 mab451hu5mu1 0.049 mab451hu6mu1 0.035 hIgG1 Not blocked
[0162] The results showed that the humanized antibody exhibited enzyme blocking activity.
[0163] Example 10 Construction of bispecific antibodies
[0164] The anti-CD73 antibody is used as the first antigen binding part, and the anti-PD-L1 fragment is used as the second antigen binding part, and genetic engineering is performed to construct a bispecific antibody, in which the anti-PD-L1 fragment and the anti-CD73 antibody are connected together through a (G4S)4 linker. During the connection process, the anti-PD-L1 fragment is connected to the carboxyl end of the heavy chain constant region domain CH3 of the IgG type structure. There is an anti-PD-L1 single domain antibody (the number of the anti-PD-L1 single domain antibody is D2hu) and the carboxyl end of the heavy chain constant region domain CH3 of the IgG structure is linked, such as Figure 1 As shown. The bispecific antibodies formed are numbered starting with "b". For example, b144mu-D12hu represents a bispecific antibody formed by the mab144 antibody (and the Fc region is mutated) as the first antigen binding part, and D2hu as the second antigen binding part. For another example, b144hu2mu1-D2hu represents a bispecific antibody formed by the second antibody after humanization of mab144 (and the Fc region has the first mutation) as the first antigen binding part, and D2hu as the second antigen binding part. And so on.
[0165] Then, the bispecific antibody protein was produced by transiently transfecting CHO-S cells, and the supernatant was collected and purified by a protein A affinity column. The purity of the purified antibody was determined by HPLC and SDS-PAGE, and the purity of the bispecific antibody was determined to be above 90%.
[0166] Example 11 Bispecific Antibody Binding Activity
[0167] CHO-K1-CD73 overexpressing cells were added to a 96-well plate at 100ul / well, with a cell concentration of 1-2×10 6 / ml. Wash with FACS buffer (i.e. PBS solution containing 2% FBS), then add different antibodies to be tested (initial antibody concentration is 200nM, 4-fold gradient dilution) at 100ul / well, and incubate at 4°C for 30min. Wash with buffer, add fluorescently labeled goat anti-human secondary antibody (manufacturer: Abcam), and incubate at 4°C for 30min. Wash with buffer, add buffer to resuspend the cells, and detect the fluorescence signal on the flow cytometer. The EC50 value of the sample to be tested was calculated using the data processing software Graphpad Prism8.0, as shown in Table 7 below.
[0168] Table 7
[0169] Antibody ID EC50(nM) b144mu1-D2hu 1.5 b144hu2mu1-D2hu 1.8 b449mu1-D2hu 0.28 b309mu1-D2hu 0.50 b451mu1-D2hu 0.67 hIgG No combination
[0170] Example 12 Determination of Bispecific Antibody Enzyme Blocking Activity
[0171] The enzymatic blocking activity of the bispecific antibody was detected by the method of Example 9, and the results are shown in Table 8-1 and Table 8-2. Figure 8 As shown in the figure, the enzyme blocking activity of the bispecific antibody is stronger than that of the positive control, at least 2 to 5 times that of the positive control.
[0172] Table 8-1
[0173]
[0174]
[0175] Table 8-2
[0176] Antibody ID EC50(nM) b144hu2mu2-D2hu 0.40 mab144hu2mu2 0.30 mab449hu4mu1 0.42 b451hu4mu1-D2hu 0.68 mab451hu4mu2 0.25 hIgG Not blocked hIgG1mu2 Not blocked
[0177] Example 13 Bispecific Antibody Reporter Gene Blocking Activity
[0178] The blocking effect of bispecific antibodies on the PD-L1 / PD-1 pathway was studied by reporter gene experiments. The experiment was completed with the help of two cell lines: Jurkat-PD1-CD3zeta-NFAT-Luc2 cell line (manufacturer: Kangyuan Bochuang Biotechnology (Beijing) Co., Ltd.) and 293T-hPD-L1 cell line (manufacturer: Kangyuan Bochuang Biotechnology (Beijing) Co., Ltd.). Jurkat-PD1-CD3zeta-NFAT-Luc2 cell line stably expresses a fusion protein composed of PD-1ECD and CD3zeta in Jurkat cells, and at the same time inserts a luciferase reporter gene driven by NF-AT; 293T-hPD-L1 cells are 293T cells expressing human PD-L1. When the two cells are co-cultured, the PD-1 / PD-L1 interaction serves as the first signal, and the intracellular CD3zeta chain serves as the second signal to transmit the activation signal inward, and the NFAT-driven luciferase reporter gene is expressed and emits fluorescence; when the PD-L1 antibody is added to the culture system, it blocks the binding of PD-1 / PD-L1, inhibits the transmission of the activation signal, and the luciferase reporter gene cannot be expressed. The experimental process is as follows:
[0179] 293T-hPD-L1 cells were cultured at 2×10 4 Jurkat-PD1-CD3zeta-NFAT-Luc2 effector cells were plated in 96-well plates at a rate of 2×10 4 / well to the 96-well plate; then add different concentrations of the test antibody (starting concentration is 60ug / ml, 4-fold gradient dilution), incubate at 37°C for 18-24h. Add 100ul of luciferase substrate ONE-Glo to each well TM Luciferase Assay system detection reagent, incubate in dark for 5 minutes; read the fluorescence signal in the 96-well plate with an ELISA reader. Draw a four-parameter curve with relative fluorescence value as the y-axis and the concentration of the antibody sample as the x-axis. Use GraphPad Prism8.0 software to analyze the curve and obtain the IC50 value of the dual antibody, as shown in Table 9-1 and Table 9-2 below.
[0180] Table 9-1
[0181]
[0182]
[0183] Table 9-2
[0184] Antibody ID IC50(nM) b144hu2mu2-D2hu 4.6 b451hu4mu2-D2hu 5.1 D2H 5.0 hIgG1mu2 Not blocked
[0185] In the description of this specification, the description with reference to the terms "embodiment", "some embodiments", "example", "specific implementation", or "implementation" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, unless they are contradictory.
[0186] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. An anti-CD73 antibody, characterized in that It includes a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises the HCDR1-3 sequences shown in SEQ ID NOs: 13, 14 and 15, and the light chain variable region comprises the LCDR1-3 sequences shown in SEQ ID NOs: 22, 23 and 32; Alternatively, the heavy chain variable region comprises the HCDR1-3 sequences shown in SEQ ID NOs: 19, 20 and 21, and the light chain variable region comprises the LCDR1-3 sequences shown in SEQ ID NOs: 36, 37 and 38.
2. An anti-CD73 antibody, characterized in that include: The HCDR1, HCDR2 and HCDR3 sequences of the heavy chain variable region as shown in SEQ ID NO:43, and the LCDR1, LCDR2 and LCDR3 sequences of the light chain variable region as shown in SEQ ID NO:50; Or the HCDR1, HCDR2 and HCDR3 sequences of the heavy chain variable region as shown in SEQ ID NO:45, and the LCDR1, LCDR2 and LCDR3 sequences of the light chain variable region as shown in SEQ ID NO:
52.
3. The antibody according to any one of claims 1 to 2, characterized in that Include: a heavy chain variable region having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence shown in SEQ ID NO:43 or 45 or 57 or 58 or 59 or 60 or 63 or 64 or 65, and A light chain variable region having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence shown in SEQ ID NO:50 or 52 or 70 or 71 or 72 or 73 or 74 or 77 or 78 or 79.
4. The antibody according to any one of claims 1 to 2, characterized in that Select at least one of the following: having a heavy chain variable region as shown in SEQ ID NO:43 and a light chain variable region as shown in SEQ ID NO:50; or having a heavy chain variable region shown in SEQ ID NO:45 and a light chain variable region shown in SEQ ID NO:52; or having a heavy chain variable region shown in SEQ ID NO:57 and a light chain variable region shown in SEQ ID NO:70; or having a heavy chain variable region shown in SEQ ID NO:58 and a light chain variable region shown in SEQ ID NO:71; or having a heavy chain variable region as shown in SEQ ID NO:59 and a light chain variable region as shown in SEQ ID NO:72; or having a heavy chain variable region as shown in SEQ ID NO:60 and a light chain variable region as shown in SEQ ID NO:73; or having a heavy chain variable region as shown in SEQ ID NO:60 and a light chain variable region as shown in SEQ ID NO:74; or having a heavy chain variable region as shown in SEQ ID NO:63 and a light chain variable region as shown in SEQ ID NO:77; or having a heavy chain variable region shown in SEQ ID NO:64 and a light chain variable region shown in SEQ ID NO:78; or It has a heavy chain variable region shown in SEQ ID NO:65 and a light chain variable region shown in SEQ ID NO:
79.
5. The antibody according to any one of claims 1 to 2, characterized in that The antibody is selected from at least one of the following groups: IgG1, IgG2, IgG3, IgG4; Optionally, the antibody or antigen-binding fragment has at least one of the following properties: (a) Inhibit CD73 enzyme activity; (b) binds human CD73 with a Kd of 10 nM or less; (c) Binds to monkey CD73 with a Kd of 10 nM or less.
6. A bispecific antibody, characterized in that: comprising a first antigen binding portion and a second antigen binding portion; The first antigen binding portion specifically binds to a first epitope, the first antigen binding portion comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region and the light chain variable region are the heavy chain variable region and the light chain variable region of the antibody according to any one of claims 1 to 5; The second antigen binding moiety specifically binds to a second epitope, the second antigen binding moiety is fused to the first antigen binding moiety, and the second antigen binding moiety specifically binds to PD-L1.
7. The bispecific antibody according to claim 6, characterized in that The heavy chain variable region and the heavy chain constant domain of the first antigen binding moiety are connected, and the light chain variable region and the light chain constant domain of the first antigen binding moiety are connected to form an IgG-like structure; The second antigen binding moiety is connected to the IgG-like structure, and the second antigen binding moiety comprises a single domain antibody that specifically binds to a second epitope; The second antigen binding moiety comprises a single domain antibody that specifically binds to a second epitope, the second epitope being PD-L1; Optionally, the second antigen binding moiety comprises CDR1, CDR2 and CDR3, and the second antigen binding moiety is selected from at least one of the following: (1) having a CDR1 sequence as shown in SEQ ID NO: 80, a CDR2 sequence as shown in SEQ ID NO: 81, and a CDR3 sequence as shown in SEQ ID NO: 82; or (2) having a CDR1 sequence as shown in SEQ ID NO: 83, a CDR2 sequence as shown in SEQ ID NO: 84, and a CDR3 sequence as shown in SEQ ID NO: 85; or (3) having a CDR1 sequence as shown in SEQ ID NO: 86, a CDR2 sequence as shown in SEQ ID NO: 87, and a CDR3 sequence as shown in SEQ ID NO: 88; or (4) having a CDR1 sequence as shown in SEQ ID NO: 80, a CDR2 sequence as shown in SEQ ID NO: 81, and a CDR3 sequence as shown in SEQ ID NO: 89; Optionally, the second antigen binding moiety is selected from: (a) having a sequence as shown in SEQ ID NO: 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99; (b) a sequence having a sequence identity of 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more compared to (a).
8. The bispecific antibody according to claim 6, characterized in that The heavy chain variable region and the heavy chain constant domain of the first antigen binding moiety are connected, and the light chain variable region and the light chain constant domain of the first antigen binding moiety are connected to form an IgG type structure; The second antigen binding moiety is linked to the carboxyl terminus (C-terminus) of the Fc region; or The second antigen binding moiety is linked to the amino terminus (N-terminus) of the heavy chain variable region or the light chain variable region of the first antigen binding moiety; or The second antigen binding portion is linked to the carboxyl terminus (C-terminus) of the light chain constant domain CL; Optionally, the bispecific antibody has at least one of the following properties: (a) specifically binds to PD-L1 with an EC50 value of 10 nM or less; (b) specifically binds to CD73 with an EC50 value of 10 nM or less; (c) having anti-tumor activity; (d) Promotes CD73 internalization.
9. A polynucleotide, characterized in that The polynucleotide encodes the antibody according to any one of claims 1 to 5 or the bispecific antibody according to any one of claims 6 to 8.
10. A construct, characterized in that Comprising the polynucleotide of claim 9.
11. A host cell, characterized in that Containing the polynucleotide according to claim 9 or the construct according to claim 10.
12. A pharmaceutical composition, characterized in that include: The antibody according to any one of claims 1 to 5, or the bispecific antibody according to any one of claims 6 to 8; and A pharmaceutically acceptable carrier.
13. A kit, characterized in that: The kit comprises the antibody according to any one of claims 1 to 5 or the bispecific antibody according to any one of claims 6 to 8.
14. A method for producing the antibody according to any one of claims 1 to 5 or the bispecific antibody according to any one of claims 6 to 8, characterized in that: include: Cultivating the host cell of claim 11, and The antibody or the bispecific antibody is collected from the culture.
15. Use of the antibody according to any one of claims 1 to 5, or the bispecific antibody according to any one of claims 6 to 8 in the preparation of an anti-cancer drug or a kit; The cancer is selected from at least one of non-small cell lung cancer, small cell lung cancer, squamous cell carcinoma, glioma, colon cancer, renal cancer, urothelial carcinoma, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, gastrointestinal cancer, esophageal cancer, cervical cancer, uterine cancer, head and neck cancer, adrenal cancer, urethral cancer, and vaginal cancer.
